Document:

EX-4.4

Table of Contents

 Exhibit 4.4 

SALESFORCE.COM, INC. 

AMENDED AND RESTATED 2004 EMPLOYEE STOCK PURCHASE PROGRAM 

1.      ESTABLISHMENT, PURPOSE AND
TERM OF PLAN. 

1.1      Establishment. The salesforce.com, inc. 2004 Employee Stock Purchase Plan
was established effective as of the effective date of the initial registration by the Company of its Stock under Section 12 of the Exchange Act (the “Effective Date”). 

1.2      Purpose. The purpose of the Plan is to advance the interests of the
Company and its stockholders by providing an incentive to attract, retain and reward Eligible Employees of the Participating Company Group and by motivating such persons to contribute to the growth and profitability of the Participating Company
Group. The Plan provides such Eligible Employees with an opportunity to acquire a proprietary interest in the Company through the purchase of Stock. The Company intends that the Plan qualify as an “employee stock purchase plan” under
Section 423 of the Code, including any amendments or replacements of such section (the “Section 423(b) Plan”), although the Company makes no undertaking nor representation to maintain
such qualification, and the Plan shall be so construed. In addition, this Plan document authorizes the grant of rights to purchase Stock that do not qualify under Section 423(b) of the Code (the
“Non-Section 423(b) Plan”) pursuant to rules, procedures or sub-plans adopted by the Board designed to
achieve tax, securities law or other Company compliance objectives in particular locations outside the United States. References to the Plan include the Section 423(b) Plan and
the Non-Section 423(b) Plan components. 
 If grants are intended to be made under the Non-Section 423(b) Plan component, they will be designated as such by the Board at or prior to the time of grant. 

1.3      Term of Plan. The Plan shall continue in effect until its termination by
the Board. 
 2.      DEFINITIONS AND
CONSTRUCTION. 

2.1      Definitions. Any term not expressly defined in the Plan but defined for
purposes of Section 423 of the Code shall have the same definition herein for purposes of the Section 423(b) Plan and, unless specifically defined otherwise therein, for
the Non-Section 423 Plan. Whenever used herein, the following terms shall have their respective meanings set forth below: 

(a)      “Applicable Laws” means the requirements relating to the administration of
equity-based awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of
any non-U.S. country or jurisdiction where Purchase Rights are, or will be, granted under the Plan. 

(b)      “Board” means the Board of Directors of the Company. If one or
more Committees have been appointed by the Board to administer the Plan, “Board” also means such Committee(s). Until and unless the Board of Directors of the Company determines otherwise, the Compensation Committee of the Board is deemed
appointed by the Board to administer the Plan and shall have all powers of the Board under the Plan (provided, however, that this is delegation is non-exclusive such that the Board of Directors shall
also be entitled to exercise all powers of the Board under the Plan). 

(c)      “Code” means the U.S. Internal Revenue Code of 1986, as amended, and
any applicable regulations promulgated thereunder. Reference to a specific section of the Code or U.S. Treasury Regulation thereunder will include such section or regulation, any valid regulation or other official applicable guidance promulgated
under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation. 

(d)      “Committee” means the Compensation Committee or other committee of the Board
or of other individuals satisfying Applicable Laws appointed by the Board, or by the Compensation Committee of the Board, duly appointed to administer the Plan and having such powers as specified by the Board. Unless the powers of the Committee have
been specifically limited, the Committee shall have all of the powers of the Board granted herein, including, without limitation, the power to amend or terminate the Plan at any time, subject to the terms of the Plan and any applicable limitations
imposed by law. 
 (e)      “Company” means salesforce.com, inc., a Delaware
corporation, or any successor corporation thereto. 

(f)      “Compensation” means, with respect to any Offering Period, base wages
or salary, overtime, bonuses, commissions, shift differentials, payments for paid time off and payments in lieu of notice. Compensation shall not include any compensation not included above. The Board, in its discretion, may, on a uniform and
nondiscriminatory basis under each Offering, establish a different definition of Compensation for a subsequent Offering Period. 

  
 1 

Table of Contents

 (g)      “Contributions” means the
payroll deductions and other additional payments that the Company may permit to be made by a Participant to fund the exercise of Purchase Rights granted pursuant to the Plan. 

(h)      “Eligible Employee” means an Employee who meets the requirements set
forth in Section 5 for eligibility to participate in the Plan. 

(i)      “Employee” means a person treated as an employee of a Participating
Company for purposes of Section 423 of the Code. A Participant shall be deemed to have ceased to be an Employee either upon an actual termination of employment or upon the corporation employing the Participant during an Offering Period ceasing
to be a Participating Company under the ESPP or, until and unless determined otherwise by the Board, upon the corporation employing the Participant during an Offering Period ceasing to be a Participating Company in the applicable Offering in which
the Participant is participating. For purposes of the Plan, an individual shall not be deemed to have ceased to be an Employee while on any military leave, sick leave, or other bona fide leave of absence approved by the Company (or the employing
Participating Company) or which is legally protected under Applicable Laws, in each case of three (3) months or less. If an individual’s leave of absence exceeds three (3) months, the individual shall be deemed to have ceased to be an
Employee on the day immediately following the expiry of three (3) months of such leave unless the individual’s right to reemployment is guaranteed either by statute or by contract. Notwithstanding the foregoing, the Board may establish
different rules to govern when a Participant ceases to be an Employee pursuant to the second sentence of this paragraph and to otherwise govern transfers of employment among Participating Companies including, without limitation, transfers of
employment between Section 423(b) Plan and Non-Section 423(b) Plan Participating Companies and between any separate Offerings established under the Plan, consistent with the applicable
requirements of Section 423 of the Code. 
 (j)      “Exchange Act” means the
Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder. 

(k)      “Fair Market Value” means, as of any date: 

(i)      If the Stock is then listed on a national or regional securities exchange or market system or is regularly quoted
by a recognized securities dealer, the closing sale price of a share of Stock (or the mean of the closing bid and asked prices if the Stock is so quoted instead) as quoted on the New York Stock Exchange or such other national or regional securities
exchange or market system constituting the primary market for the Stock, or by such recognized securities dealer, as reported in The Wall Street Journal or such other source as the Company deems reliable. If the relevant date does not fall on a day
on which the Stock has traded on such securities exchange or market system or has been quoted by such securities dealer, the date on which the Fair Market Value is established shall be the last day on which the Stock was so traded or quoted prior to
the relevant date, or such other appropriate day as determined by the Board, in its discretion. 
 (ii)      If, on the
relevant date, the Stock is not then listed on a national or regional securities exchange or market system or regularly quoted by a recognized securities dealer, the Fair Market Value of a share of Stock shall be as determined in good faith by the
Board. 

(l)      “Non-Section 
423(b) Plan” means an employee stock purchase plan which does not meet the requirements set forth in Section 423(b) of the Code, as amended. 

(m)      “Offering” means an offering of Stock as provided in Section 6,
including any separate Offerings under the Section 423(b) Plan and any separate Offerings under the Non-Section 423(b) Plan as may be designated by the Board (the terms of which need not be
identical) in which Eligible Employees of one or more Participating Companies will participate. Until and unless the Board determines otherwise, the Employees participating in
the Non-Section 423(b) Plan will not participate in the same Offering or Offerings as Employees participating in the Section 423(b) Plan, even if the dates of the applicable Offering Period
for the Non-Section 423(b) Plan component and one or more Offerings under the Section 423(b) Plan component are identical. 

(n)      “Offering Date” means, for any Offering, the first day of the Offering
Period. 
 (o)      “Offering Period” means an Offering Period established in
accordance with Section 6. 
 (p)      “Parent Corporation” means any
present or future “parent corporation” of the Company, as defined in Section 424(e) of the Code. 

(q)      “Participant” means an Eligible Employee who has become a participant
in an Offering Period in accordance with Section 7 and remains a participant in accordance with the Plan. 

(r)      “Participating Company” means the Company and any Parent Corporation
or Subsidiary Corporation designated by the Board as a corporation the Employees of which may, if Eligible Employees, participate in the Plan. The Board shall have the sole and absolute discretion to determine from time to time which Parent
Corporations or Subsidiary Corporations shall be Participating Companies. The Board may determine that some or all Employees of any Participating Company shall participate in
the Non-Section 423(b) Plan. 

  
 2 

Table of Contents

 (s)      “Participating Company
Group” means, at any point in time, the Company and all other corporations collectively which are then Participating Companies. 

(t)      “Plan” means the salesforce.com, inc. 2004 Employee Stock Purchase
Plan, which includes a Section 423(b) Plan and a Non-Section 423(b) Plan. 

(u)      “Purchase Date” means, for any Purchase Period, the first Trading Day
on or after June 15 and December 15 of each Purchase Period. 
 (v)      “Purchase
Period” means a Purchase Period established in accordance with Section 6. 

(w)      “Purchase Price” means the price at which a share of Stock may be
purchased under the Plan, as determined in accordance with Section 9. 

(x)      “Purchase Right” means an option granted to a Participant pursuant to
the Plan to purchase such shares of Stock as provided in Section 8, which the Participant may or may not exercise during the Offering Period in which such option is outstanding. Such option arises from the right of a Participant to withdraw any
accumulated payroll deductions of the Participant not previously applied to the purchase of Stock under the Plan and to terminate participation in the Plan at any time during an Offering Period. 

(y)      “Section 423(b) Plan” means an
employee stock purchase plan which is designed to meet the requirements set forth in Section 423(b) of the Code, as amended. The provisions of the Section 423(b) Plan shall be construed, administered and enforced in accordance with
Section 423(b) of the Code. 
 (z)      “Stock” means the common stock
of the Company, as adjusted from time to time in accordance with Section 4.2. 

(aa)      “Subscription Agreement” means an agreement in such form and provided in
such manner as specified by the Company from time to time (in its discretion and on a uniform and nondiscriminatory basis), including through an electronic or other enrollment procedure prescribed by the Company, stating an Employee’s election
to participate in the Plan and authorizing payroll deductions under the Plan from the Employee’s Compensation. The form and content of the Subscription Agreement may, in the Company’s discretion, be similar to the form attached hereto in
Appendix A. 
 (bb)      “Subscription Date” means the last business day
prior to the Offering Date of an Offering Period or such earlier date as the Company shall establish. 

(cc)      “Subsidiary Corporation” means any present or future “subsidiary
corporation” of the Company, as defined in Section 424(f) of the Code. 

(dd)      “Trading Day” means a day on which the national stock exchanges and
the Nasdaq System are open for trading. 
 (ee)      “U.S. Treasury Regulations”
means the Treasury regulations of the Code. Reference to a specific Treasury Regulation or Section of the Code shall include such Treasury Regulation or Section, any valid regulation promulgated under such Section, and any comparable provision of
any future legislation or regulation amending, supplementing or superseding such Section or regulation. 

2.2      Construction. Captions and titles contained herein are for convenience
only and shall not affect the meaning or interpretation of any provision of the Plan. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term “or” is
not intended to be exclusive, unless the context clearly requires otherwise. 

3.      
ADMINISTRATION. 

3.1      Administration by the Board. The Plan shall be administered by the Board.
All questions of interpretation of the Plan, of any form of agreement or other document employed by the Company in the administration of the Plan, or of any Purchase Right shall be determined by the Board, and such determinations shall be final,
binding and conclusive upon all persons having an interest in the Plan or the Purchase Right, unless fraudulent or made in bad faith, and shall be given the maximum deference permitted by law. Subject to the provisions of the Plan, the Board shall
determine all of the relevant terms and conditions of Purchase Rights; provided, however, that, with respect to the Section 423(b) Plan, all Participants granted Purchase Rights pursuant to an Offering shall have the same rights and privileges
within the meaning of Section 423(b)(5) of the Code and the U.S. Treasury Regulations thereunder. 

  
 3 

Table of Contents

 Notwithstanding any provision to the contrary in the Plan, and, with respect to the
Section 423(b) Plan, to the extent permissible under Section 423 of the Code and U.S. Treasury Regulations promulgated thereunder (and other Internal Revenue Service guidance), the Board may adopt rules or procedures relating to the
operation and administration of the Plan to accommodate the specific requirements of local laws and procedures for jurisdictions outside of the United States. Without limiting the generality of the foregoing, the Board is specifically authorized to
adopt rules and procedures regarding eligibility to participate, handling of Contributions, making of Contributions to the Plan, defining eligible Compensation, establishment of bank or trust accounts to hold Contributions, conversion of local
currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures and handling of stock certificates which vary with local requirements. The Board also is authorized to determine that, to the
extent permitted by U.S. Treasury Regulation Section 1.423-2(f), the terms of a Purchase Right granted under the Plan or an Offering to citizens or residents of
a non-U.S. jurisdiction will be less favorable than the terms of Purchase Rights granted under the same Offering to employees resident solely in the U.S. 

The Board may also adopt rules, procedures or sub-plans applicable to particular Participating
Companies or locations, which sub-plans may be designed to be outside the scope of Section 423 of the Code. The rules of such sub-plans may take
precedence over other provisions of this Plan, with the exception of Section 2.1(r), Section 4.1 and Section 4.2, but unless otherwise superseded by the terms of such sub-plan, the
provisions of this Plan shall govern the operation of such sub-plan. To the extent inconsistent with the requirements of Section 423,
such sub-plan shall be considered part of the Non-Section 423(b) Plan, and rights granted thereunder shall not be required by the terms of the
Plan to comply with Section 423 of the Code. Unless otherwise determined by the Board, the Employee eligible to participate in each sub-plan will participate in a separate Offering. 

Any and all actions, decisions and determinations taken or made by the Board in the exercise of its discretion pursuant to the Plan or any agreement
thereunder (other than determining questions of interpretation pursuant to the second sentence of this Section 3.1) shall be final, binding and conclusive upon all persons having an interest therein. All expenses incurred in connection with the
administration of the Plan shall be paid by the Company. 

3.2      Authority of
Officers. Any officer of the Company shall have the authority to act on behalf of the Company with respect to any matter, right, obligation, determination or election that is the responsibility of or that is allocated to the Company herein,
provided that the officer has apparent authority with respect to such matter, right, obligation, determination or election. 
 
3.3      Policies and Procedures Established by the Company. Without regard to whether any Participant’s Purchase Right may be considered
adversely affected, the Company may, from time to time, consistent with the Plan and, with respect to the Section 423(b) Plan, the requirements of Section 423 of the Code, establish, change or terminate such rules, guidelines, policies,
procedures, limitations, or adjustments as deemed advisable by the Company, in its discretion, for the proper administration of the Plan, including, without limitation, to (a) establish a minimum Contribution amount required for participation
in an Offering, (b) limit the frequency and/or number of changes permitted in the rate of Contribution during an Offering, (c) designate separate Offerings, (d) terminate or change the Offering Periods or Purchase Periods,
(e) establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, (f) establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward
the purchase of Stock for each Participant properly correspond with Contribution amounts, (g) permit Contributions greater than or less than the amount designated by a Participant in order to adjust for the Company’s delay or mistake in
processing a Subscription Agreement or in otherwise effecting a Participant’s election under the Plan or, for purposes of the Section 423(b) Plan, as advisable to comply with the requirements of Section 423 of the Code,
(h) determine the date and manner by which the Fair Market Value of a share of Stock is determined for purposes of administration of the Plan, and (i) establish such other limitations or procedures as the Board determines in its sole
discretion advisable that are consistent with the Plan. With respect to the Section 423(b) Plan, all such actions by the Company shall be taken consistent with the requirement under Section 423(b)(5) of the Code that all Participants
granted Purchase Rights pursuant to an Offering shall have the same rights and privileges within the meaning of such section. 
 
3.4      Indemnification. In addition to such other rights of indemnification as they may have as members of the Board or officers or employees
of the Participating Company Group, members of the Board and any officers or employees of the Participating Company Group to whom authority to act for the Board or the Company is delegated shall be indemnified by the Company against all reasonable
expenses, including attorneys’ fees, actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be a party by reason of any
action taken or failure to act under or in connection with the Plan, or any right granted hereunder, and against all amounts paid by them in settlement thereof (provided such settlement is approved by independent legal counsel selected by the
Company) or paid by them in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such person is liable for gross negligence, bad
faith or intentional misconduct in duties; provided, however, that within sixty (60) days after the institution of such action, suit or proceeding, such person shall offer to the Company, in writing, the opportunity at its own expense to handle
and defend the same. 

4.      SHARES
SUBJECT TO PLAN. 

4.1      Maximum Number of Shares
Issuable. Subject to adjustment as provided in Section 4.2, the maximum aggregate number of shares of Stock that may be issued under the Plan shall be thirty-seven million (37,000,000),
and shall consist of authorized but unissued or reacquired 

  
 4 

Table of Contents

 
shares of Stock, or any combination thereof. For avoidance of doubt, the limitation set forth in this section may be used to satisfy purchases of shares of Stock under either the
Section 423(b) Plan or the Non-Section 423(b) Plan. If an outstanding Purchase Right for any reason expires or is terminated or canceled without the issuance of shares of Stock thereunder,
the shares of Stock allocable to the unexercised portion of that Purchase Right shall again be available for issuance under the Plan. 
 
4.2      Adjustments for Changes in Capital Structure. Subject to any required action by the stockholders of the Company, in the event of any change in the Stock effected without receipt of consideration
by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares, or similar change in the capital structure of the Company, or in the event of payment of a dividend
or distribution to the stockholders of the Company in a form other than Stock (excepting normal cash dividends) that has a material effect on the Fair Market Value of shares of Stock, appropriate adjustments shall be made in the number and class of
shares subject to the Plan, the limit on the shares which may be purchased by any Participant during an Offering (as described in Sections 8.1) and each Purchase Right, and in the Purchase Price in order to prevent dilution or enlargement of
Participants’ rights under the Plan. For purposes of the foregoing, conversion of any convertible securities of the Company shall not be treated as “effected without receipt of consideration by the Company.” Any fractional share
resulting from an adjustment pursuant to this Section 4.2 shall be rounded down to the nearest whole number, and in no event may the Purchase Price be decreased to an amount less than the par value, if any, of the stock subject to the Purchase
Right. The adjustments determined by the Board pursuant to this Section 4.2 shall be final, binding and conclusive. 

5.      ELIGIBILITY.

 5.1      Employees Eligible to Participate. Each Employee of a
Participating Company is eligible to participate in the Plan and shall be deemed an Eligible Employee, except the following: 

(a)      Any Employee who is customarily employed by the Participating Company Group for twenty (20) hours or less
per week; or 
 (b)      Any Employee who is customarily employed by the Participating Company Group for not more than
five (5) months in any calendar year. 
 Notwithstanding the foregoing, the Board, in its discretion, from time to time may, prior to an Offering
Date for all Purchase Rights to be granted on such Offering Date in an Offering, to the extent permitted by Section 423 of the Code and the regulations thereunder, determine (for each Offering under the Section 423(b) Plan, on a uniform
and nondiscriminatory basis or as otherwise permitted by Treasury Regulation Section 1.423-2) that the definition of Eligible Employee will or will not include an individual if he or she:
(i) has not completed at least two (2) years of service since his or her last hire date (or, with respect to a decision to include an individual, such lesser period of time as may be determined by the Board in its discretion),
(ii) customarily works not more than twenty (20) hours per week (or, with respect to a decision to include an individual, such lesser period of time as may be determined by the Board in its discretion), (iii) customarily works not
more than five (5) months per calendar year (or, with respect to a decision to include an individual, such lesser period of time as may be determined by the Board in its discretion), (iv) is a highly compensated employee within the meaning
of Section 414(q) of the Code, or (v) is a highly compensated employee within the meaning of Section 414(q) of the Code with compensation above a certain level or is an officer or subject to the disclosure requirements of
Section 16(a) of the Exchange Act, provided the exclusion is applied with respect to each Offering under the Section 423(b) Plan in an identical manner to all highly compensated individuals of the employing Participating Companies whose
Employees are participating in that Offering. Each exclusion shall be applied with respect to an Offering under the Section 423(b) Plan in a manner complying with U.S. Treasury
Regulation Section 1.423-2(e). Such exclusions may be applied with respect to an Offering under the Non-Section 423(b) Plan without regard
to the limitations of Treasury Regulation Section 1.423-2. 
 Further, the Board, in its discretion,
may, prior to an Offering Date for an Offering under the Non-Section 423(b) Plan, determine to exclude from Plan participation some or all Employees of a Participating Company designated to
participate in such Non-Section 423(b) Plan Offering. Finally, Employees who are citizens or residents of a non-U.S. jurisdiction (without regard to whether they also are citizens or residents of the
United States or resident aliens (within the meaning of Section 7701(b)(1)(A) of the Code)) may be excluded from participation in the Plan or an Offering if the participation of such Employees is prohibited under the laws of the applicable
jurisdiction or if complying with the laws of the applicable jurisdiction would cause the Plan or an Offering to violate Section 423 of the Code. 

5.2    Exclusion of Certain Stockholders. Notwithstanding any provision of the Plan to the
contrary, no Employee shall be treated as an Eligible Employee and granted a Purchase Right under the Plan if, immediately after such grant, the Employee would own or hold options to purchase stock of the Company or of any Parent Corporation or
Subsidiary Corporation possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of such corporation or a related corporation, as determined in accordance with Section 423(b)(3) of the Code
and the applicable U.S. Treasury Regulations of Section 423 of the Code. For purposes of this Section 5.2, the attribution rules of Section 424(d) of the Code shall apply in determining the stock ownership of such Employee. 

  
 5 

Table of Contents

 
5.3    Determination by Company. The Company shall determine in good faith and in the exercise of its discretion whether an
individual has become or has ceased to be an Employee or an Eligible Employee and the effective date of such individual’s attainment or termination of such status, as the case may be. For purposes of an individual’s participation in or
other rights, if any, under the Plan as of the time of the Company’s determination, all such determinations by the Company shall be final, binding and conclusive, notwithstanding that the Company or any court of law or governmental agency
subsequently makes a contrary determination. 
 
6.    OFFERINGS. 

The Board previously determined that no Offerings would commence under the Plan until further approval by the Board. Beginning on December 15, 2011,
the Plan shall be implemented by consecutive, overlapping Offering Periods of approximately twelve (12) months duration (individually, an “Offering Period”) commencing on the first Trading Day on or
after June 15 and December 15 of each year and ending on the first Trading Day on or after June 15 and December 15, respectively. Notwithstanding the foregoing, the Board may establish additional or alternative sequential or
overlapping Offering Periods, a different duration for one or more Offerings or Offering Periods or different commencing, purchase or ending dates for such Offering Periods with respect to future offerings without stockholder approval if such change
is announced prior to the scheduled beginning of the first Offering Period to be affected thereafter; provided, however, that no Offering Period may have a duration exceeding twenty-seven (27) months. Unless and until the Board determines
otherwise in its discretion, each Offering Period shall consist of two (2) consecutive purchase periods each having a duration of approximately six (6) months (individually, a “Purchase Period”),
commencing on one Purchase Date and ending with the next Purchase Date, except that the first Purchase Period of any Offering Period will commence on the Offering Date and end with the next Purchase Date. Further, if the Board so determines,
Eligible Employees of the Company and/or of any Participating Company will be deemed to participate in a separate Offering under the Section 423(b) Plan, even if the dates of the applicable Offering Period of each such Offering are identical,
provided that the terms of participation are the same within each separate Offering, as determined in accordance with the requirements of Section 423 of the Code. 

7.    PARTICIPATION IN THE PLAN. 

7.1    Initial Participation. An Eligible Employee may become a Participant in an Offering Period by delivering or submitting a properly completed Subscription Agreement in such form
and manner prescribed by the Company by the Subscription Date established by the Company for that Offering Period. An Eligible Employee who does not deliver or submit a properly completed Subscription Agreement on or before the Subscription Date for
an Offering Period shall not participate in the Plan for that Offering Period or for any subsequent Offering Period unless the Eligible Employee subsequently delivers or submits a properly completed Subscription Agreement on or before the
Subscription Date for such subsequent Offering Period. An Employee who becomes an Eligible Employee after the Offering Date of an Offering Period shall not be eligible to participate in that Offering Period but may participate in any subsequent
Offering Period provided the Employee is still an Eligible Employee as of the Offering Date of such subsequent Offering Period. 
 
7.2    Continued Participation. A
Participant shall automatically participate in the next Offering Period commencing immediately after (including an Offering Period beginning the same day) the last Purchase Date of each Offering Period in which the Participant participates provided
that the Participant remains an Eligible Employee on the Offering Date of the new Offering Period and has not either (a) withdrawn from the Plan pursuant to Section 12.1, (b) decreased his or her rate of Contributions to zero percent
(0%) for the then-current Offering Period pursuant to Section 10.3, or (c) terminated employment as provided in Section 13. A Participant who may automatically participate in a subsequent Offering Period, as provided in this Section,
is not required to deliver or submit any additional Subscription Agreement for the subsequent Offering Period in order to continue participation in the Plan. However, a Participant may deliver or submit a new Subscription Agreement for a subsequent
Offering Period in accordance with the procedures set forth in Section 7.1 if the Participant desires to change any of the elections contained in the Participant’s then effective Subscription Agreement. 

8.    RIGHT TO PURCHASE SHARES. 

8.1    Grant of Purchase Right. Except as otherwise provided below, on the Offering Date of each Offering Period, each Participant in such Offering Period shall be granted automatically
a Purchase Right consisting of an option to purchase on each Purchase Date during such Offering Period (at the applicable Purchase Price) up to a maximum of that number of whole shares of Stock determined by dividing Twelve Thousand Five Hundred
Dollars ($12,500) by the Fair Market Value of a Share of Stock on the Offering Date of such Offering Period, subject to adjustment under Section 4.2 above; as a result, in no event will a Participant be eligible to purchase during any Offering
Period that number of whole shares of Stock determined by dividing Twenty-Five Thousand Dollars ($25,000) by the Fair Market Value of a Share of Stock on the Offering Date of such Offering Period, subject to adjustment under Section 4.2 above.
The Board may, in its discretion and prior to the Offering Date of any Offering Period, (i) change the maximum number of shares of Stock that may be purchased by a Participant in such Offering Period or on any Purchase Date within an Offering
Period or (ii) specify a maximum aggregate number of shares that may be purchased by all Participants in an Offering Period or on any Purchase Date within an Offering Period. Further, the Board may limit the number or value of the shares of
Stock made available for purchase in a qualified period (e.g., twelve (12) month period) by Participants in specified countries, locations or Participating Companies, if necessary to avoid securities law filings, achieve tax
objectives or to meet other Company compliance objectives in particular locations outside the United States, provided that any such limitation is imposed under the Non-Section 423(b) Plan or,
with respect to any Offering under the Section 423(b) Plan, is imposed on an equal basis to all 

  
 6 

Table of Contents

 
Participants under such Offering or as otherwise permitted in accordance with Section 423 of the Code and the U.S.
Treasury Regulations thereunder. No Purchase Right shall be granted on an Offering Date to any person who is not, on such Offering Date, an Eligible Employee. 

8.2    Calendar
Year Purchase Limitation. Notwithstanding any provision of the Plan to the contrary, no Participant shall be granted a Purchase Right which permits his or her right to purchase shares of Stock under the Plan to accrue at a rate which, when
aggregated with such Participant’s rights to purchase shares under all other employee stock purchase plans of a Participating Company intended to meet the requirements of Section 423 of the Code, exceeds Twenty-Five Thousand Dollars
($25,000) in Fair Market Value (or such other limit, if any, as may be imposed by the Code) for each calendar year in which such Purchase Right is outstanding at any time. For purposes of the preceding sentence, the Fair Market Value of shares
purchased during a given Offering Period shall be determined as of the Offering Date for such Offering Period. The limitation described in this Section shall be applied in conformance with Section 423(b)(8) of the Code and the applicable
U.S. Treasury Regulations thereunder. 

9.    
PURCHASE PRICE. 
 The Purchase Price at which each share
of Stock may be acquired in an Offering Period upon the exercise of all or any portion of a Purchase Right shall be established by the Board; provided, however, that the Purchase Price on each Purchase Date shall not be less than eighty-five percent
(85%) of the lesser of (a) the Fair Market Value of a share of Stock on the Offering Date of the Offering Period or (b) the Fair Market Value of a share of Stock on the Purchase Date. Subject to adjustment as provided below or in
Section 23 and unless otherwise provided by the Board, the Purchase Price for each Offering Period shall be eighty-five percent (85%) of the lesser of (a) the Fair Market Value of a share of Stock on the Offering Date of the Offering
Period or (b) the Fair Market Value of a share of Stock on the Purchase Date. Notwithstanding the foregoing, in the event that (i) the stockholders of the Company approve an amendment to the Plan to increase the maximum aggregate number of
shares of Stock issuable under the Plan in accordance with Section 4.1, (ii) all or any portion of such additional shares of Stock (the “Additional Shares”) are to be issued pursuant to an
Offering Period in progress at the time of such stockholder approval and (iii) the Fair Market value per share of Stock on the date of such stockholder approval (the “Approval Date”) is greater than
the Fair Market value per share of Stock on the Offering Date of such Offering Period, then, the Board may, in its discretion and without the consent of any Participant, adjust the Purchase Price for such Offering Period to be an amount equal to
eighty-five percent (85%) (or such other percentage as in effect prior to such adjustment) of the lesser of (a) the Fair Market Value of a share of Stock on the Approval Date or (b) the Fair Market Value of a share of Stock on the
Purchase Date. 

10.    
ACCUMULATION OF PURCHASE PRICE THROUGH PAYROLL DEDUCTION.

 Except as provided in Section 10.4, shares of Stock acquired pursuant to the exercise of all or any portion of a Purchase Right may be paid for
only by means of payroll deductions from the Participant’s Compensation accumulated during the Offering Period for which such Purchase Right was granted, subject to the following: 

10.1    Amount of
Payroll Deductions. Except as otherwise provided herein, the amount to be deducted under the Plan from a Participant’s Compensation or other Contributions (to the extent permitted by the Board) made on each pay day during an Offering
Period shall be determined by the Participant’s Subscription Agreement. The Subscription Agreement shall set forth the percentage of the Participant’s Compensation to be deducted or other Contributions made on each pay day during an
Offering Period in whole percentages of not less than two percent (2%) (except as a result of an election pursuant to Section 10.3 to stop payroll deductions during an Offering) or more than fifteen percent (15%) of the Compensation
which he or she receives on each pay day during the Offering Period; provided, however, that should a pay day occur on a Purchase Date, a Participant will have any payroll deductions made on such day applied to his or her account under the
subsequent Purchase Period or Offering Period. The Board may change the foregoing limits on payroll deductions effective as of any Offering Date. A Participant’s Subscription Agreement will remain in effect for successive Offering Periods
unless terminated as provided in Section 
12 hereof. 
 10.2   
 Commencement of Contributions. Payroll deductions for a Participant shall commence on the first pay day on or following the Offering Date and shall end on the last pay day prior to the end of the Offering Period unless sooner
altered or terminated as provided herein. 
 
10.3    Election to Change or Stop Contributions. During an Offering Period, a Participant may elect to decrease the rate of or to stop Contributions of his or her Compensation by delivering or submitting to the
Company an amended Subscription Agreement or following such other procedure prescribed by the Company to authorize such change and completed on or before a date established by the Company from time to time in a nondiscriminatory manner and announced
to the Participants. Such election to change or stop contributions will be implemented prior to the beginning of the first pay period for which such election is to be effective as established by the Company from time to time and announced to the
Participants. A Participant who elects, effective following the first pay day of an Offering Period, to decrease the rate of his or her Contributions to zero percent (0%) shall nevertheless remain a Participant in the current Offering Period
assuming he or she remains otherwise eligible, and unless such Participant withdraws from the Plan as provided in Section 12.1; provided, however, that if such decrease of a Participant’s rate of Contributions to zero percent (0%) occurs
during the first Purchase Period during and Offering Period, he or she shall remain in such first Purchase Period (assuming he or she remains otherwise 

  
 7 

Table of Contents

 
eligible and unless such Participant withdraws from the Plan as provided in Section 12.1) through the purchase of shares of Stock on
the Purchase Date for such Purchase Period but automatically shall be deemed to withdraw from the second Purchase Period in such Offering Period. The Board may, in its sole discretion, limit the nature and/or number of Contribution rate changes that
may be made by Participants during any Offering Period or Purchase Period and may establish such other conditions or limitations as it deems appropriate for Plan administration. Until and unless determined otherwise by the Board, a Participant may
elect one decrease to his or her rate of Contributions per Purchase Period, but no increases to his or her rate of Contributions per Offering Period or Purchase Period. 

10.4    Alternative Contributions. The Board, in its discretion, may permit
Participants in a specified Offering under the Section 423(b) Plan or in an Offering under the Non-Section 423(b) to make Contributions to the Plan through cash, check or other means in
lieu of payroll deductions set forth in the Subscription Agreement prior to each Purchase Date of each Purchase Period; provided, however, that, with respect to Offerings under the Section 423(b) Plan, payment through means other than payroll
deductions shall be permitted only if the Participant has not already had the maximum permitted amount withheld through payroll deductions during the Purchase Period or Offering Period and such other payment means meet the requirements of and are
permissible under Section 423(b) and the U.S. Treasury Regulations thereunder. Unless otherwise required by the context, references to “payroll deductions” in this Plan shall be construed as including such alternative Contributions as
may be permitted by the Board. 
 10.5    Administrative Suspension of Contributions. The
Company may, in its sole discretion, suspend a Participant’s Contributions under the Plan as the Company deems advisable to avoid accumulating Contributions in excess of the amount that could reasonably be anticipated to purchase the maximum
number of shares of Stock permitted (a) under the Participant’s Purchase Right or (b) during a calendar year under the limit set forth in Section 8.2. Unless the Participant has either withdrawn from the Plan as provided in
Section 12.1 or has ceased to be an Eligible Employee, Contributions shall be resumed at the rate specified in the Participant’s then effective Subscription Agreement either (i) at the beginning of the next Offering Period if the
reason for suspension was due to clause (a) in the preceding sentence or (ii) at the beginning of the next Offering Period having a first Purchase Date that falls within the subsequent calendar year if the reason for suspension was clause
(b) in the preceding sentence. 
 10.6    Participant Accounts. Individual
bookkeeping accounts shall be maintained for each Participant. All of a Participant’s Contributions shall be credited to such Participant’s Plan account and shall be deposited with the general funds of the Company. All such Contributions
received or held by the Company may be used by the Company for any corporate purpose. The Company will not be obligated to segregate such Contributions, unless otherwise required under Applicable Laws in which case, any alternative method of deposit
shall apply with respect to any Offering under the Section 423 Plan, on a uniform and non-discriminatory manner to all Participants under such Offering or as otherwise permitted in accordance
with Section 423 of the Code and the U.S. Treasury Regulations thereunder, or shall apply under the Non-Section 423(b) Plan. Until the shares of Stock are issued (as evidenced by the
appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), a Participant will only have the rights of an unsecured creditor with respect to such shares of Stock, and no right to vote or receive dividends or
any other rights as a stockholder will exist with respect to such shares of Stock. 
 10.7    No
Interest Paid. Interest shall not be paid on sums deducted from a Participant’s Compensation pursuant to the Plan or otherwise credited to the Participant’s Plan account, unless payment of interest is required under Applicable
Law, as determined by the Company, in which case either (i) with respect to any Offering under the Section 423(b) Plan in which any Participant is subject to such Applicable Law requirement, the payment of interest shall apply to all
Participants in such Offering except to the extent otherwise permitted by U.S. Treasury Regulation Section 1.423-2(f), or (ii) with respect to any Offering under the
Non-Section 423(b) 
Plan, the payment of interest shall apply as determined by the Company. 
 11.    
PURCHASE OF 
SHARES. 
 11.1    Exercise of
Purchase Right. On each Purchase Date of an Offering Period, each Participant who has not withdrawn from the Plan and whose participation in the Offering has not otherwise terminated before such Purchase Date shall automatically acquire
pursuant to the exercise of the Participant’s Purchase Right the number of whole shares of Stock determined by dividing (a) the total amount of the Participant’s payroll deductions accumulated in the Participant’s Plan account
during the Offering Period and not previously applied toward the purchase of Stock by (b) the Purchase Price, subject to the limitations in Section 8 above. In addition, no fractional shares of Stock will be purchased. No shares of Stock
shall be purchased on a Purchase Date on behalf of a Participant whose participation in the Offering or the Plan has terminated before such Purchase Date. 

11.2    Pro Rata Allocation of Shares. If the number of shares of Stock which might be
purchased by all Participants on a Purchase Date exceeds the number of shares of Stock available in the Plan as provided in Section 4.1 or the maximum aggregate number of shares of Stock that may be purchased on such Purchase Date pursuant to a
limit established by the Board pursuant to Section 8.1, the Company shall make a pro rata allocation of the shares available in as uniform a manner as practicable and as the Company determines to be equitable among all Participants exercising
Purchase Rights to purchase Stock on such Purchase Date and may either continue all Offering Periods then in effect or terminate any or all Offering Periods then in effect pursuant to Section 24. Any fractional share resulting from such pro
rata allocation to any Participant shall be disregarded. 

  
 8 

Table of Contents

 11.3    Delivery of Certificates. As soon
as practicable after each Purchase Date, the Company shall arrange the delivery to each Participant of the shares acquired by the Participant on such Purchase Date by electronic or other means determined by the Company in its sole discretion and
pursuant to rules established by the Board. The Company may permit or require that shares be deposited directly with a broker designated by the Company or to a designated agent of the Company, and the Company may utilize electronic or automated
methods of share transfer. The Company may require that shares be retained with such broker or agent for a designated period of time and/or may establish procedures to permit tracking of disqualifying dispositions of such shares. Shares to be
delivered to a Participant under the Plan shall be registered in the name of the Participant, or, if requested by the Participant, in the name of the Participant and his or her spouse, or, if applicable, in the names of the heirs of the Participant.

 11.4    Return of Cash Balance. Any cash balance remaining in a Participant’s Plan
account following any Purchase Date shall be refunded to the Participant as soon as practicable after such Purchase Date, without interest. Notwithstanding the foregoing, the Committee may, in its discretion and to the extent permissible under
Section 423 of the Code and U.S. Treasury Regulations promulgated thereunder (and other Internal Revenue Service guidance), determine that, if the Contributions to be returned to a Participant pursuant to the preceding sentence is less than the
amount that would have been necessary to purchase an additional whole share of Stock on such Purchase Date, the Company shall retain the cash balance in the Participant’s Plan account to be applied toward the purchase of shares of Stock in the
subsequent Offering Period, subject to earlier withdrawal by the Participant as provided in Section 12. 

11.5    Tax Withholding. At the time a Participant’s Purchase Right is exercised, in
whole or in part, or at the time a Participant disposes of some or all of the shares of Stock he or she acquires under the Plan (or any other time that a taxable event related to the Plan occurs), the Participant shall make adequate provision for
the U.S. federal, state, local and or any other tax liability payable to any authority including taxes imposed by jurisdictions outside of the U.S., national insurance, social security or other tax withholding obligations, if any, of the
Participating Company Group which arise upon exercise of the Purchase Right or upon such disposition of shares (or any other time that a taxable event related to the Plan occurs), as applicable. The Participating Company Group may, but shall not be
obligated to, withhold from the Participant’s compensation or any other payments due the Participant the amount necessary to meet such withholding obligations or withhold from the proceeds of the sale of shares of Stock or any other method of
withholding the Participating Company Group deems appropriate to the extent permitted by U.S. Treasury Regulation Section 1.423-2(f), including any withholding required to make available to the Company or
the employing Participating Company any tax deductions or benefit attributable to the sale or early disposition of shares of Stock by the Participant. 

11.6    Expiration of Purchase Right. Any portion of a Participant’s Purchase Right
remaining unexercised after the end of the Offering Period to which the Purchase Right relates shall expire immediately upon the end of the Offering Period. 

11.7    Provision of Reports and Stockholder Information to Participants. Individual
accounts shall be maintained for each Participant in the Plan. Each Participant who has exercised all or part of his or her Purchase Right shall receive, at least annually, a report of such Participant’s Plan account setting forth the
Contributions credited to his or her Plan account, the number of shares of Stock purchased, the Purchase Price for such shares, the date of purchase and the cash balance, if any, remaining. The report required by this Section may be delivered
in such form and by such means, including by electronic transmission, as the Company may determine. In addition, each Participant shall be provided any information required by Applicable Laws. 

12.    WITHDRAWAL FROM 
PLAN. 
 12.1    Voluntary
Withdrawal from the Plan. A Participant may withdraw from the Plan by delivering or submitting to the Company a notice of withdrawal on a form and in such manner and in such time frame as provided by the Company for this purpose (which may,
in the Company’s discretion, be similar to the form notice of withdrawal attached hereto in Appendix A). Such withdrawal may be elected at any time prior to the end of an Offering Period; provided, however, that if a Participant withdraws from
the Plan after a Purchase Date, the withdrawal shall not affect shares of Stock acquired by the Participant on such Purchase Date. A Participant who voluntarily withdraws from the Plan is prohibited from resuming participation in the Plan in the
same Offering from which he or she withdrew, but may participate in any subsequent Offering by again satisfying the requirements of Sections 5 and 7.1. The Company may impose, from time to time, a requirement that the notice of withdrawal from the
Plan be on file with the Company for a reasonable period prior to the effectiveness of the Participant’s withdrawal. 

12.2    Return of Payroll Deductions. Upon a Participant’s voluntary withdrawal from
the Plan pursuant to Section 12.1, the Participant’s accumulated Plan account balance which has not been applied toward the purchase of shares of Stock shall be refunded to the Participant as soon as practicable after the withdrawal,
without the payment of any interest (subject to Section 10.7 above), and the Participant’s interest in the Plan and the Offering shall terminate. Such amounts to be refunded in accordance with this Section may not be applied to any other
Offering under the Plan. A Participant’s withdrawal from the Plan will not have any effect upon his or her eligibility to participate in any similar plan which may hereafter be adopted by the Company or in any Offering Periods which commence
after the termination of the Offering Period during which the Participant withdrew. 

  
 9 

Table of Contents

13.    TERMINATION OF 
EMPLOYMENT OR ELIGIBILITY. 
 Upon a
Participant’s ceasing, prior to a Purchase Date, to be an Employee for any reason, including retirement, disability or death, or upon the failure of a Participant to remain an Eligible Employee, the Participant’s participation in the Plan
shall terminate immediately. In such event, the Participant’s Plan account balance which has not been applied toward the purchase of shares shall, as soon as practicable, be returned to the Participant or, in the case of the Participant’s
death, to the executor or administrator of the Participant’s estate, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver the Participant’s Plan account
balance to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate, and all of the Participant’s rights
under the Plan shall terminate. Interest shall not be paid on sums returned pursuant to this Section 13. A Participant whose participation has been so terminated may again become eligible to participate in the Plan by satisfying the
requirements of Sections 5 and 7.1. 

14.    CHANGE IN 
CONTROL. 

14.1    Definitions. 

(a)    An “Ownership Change Event” shall be deemed to have occurred if any of the
following occurs with respect to the Company: (i) the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of more than fifty percent (50%) of the voting stock of the Company;
(ii) a merger or consolidation in which the Company is a party; (iii) the sale, exchange, or transfer of all or substantially all of the assets of the Company; or (iv) a liquidation or dissolution of the Company. 

(b)    A “Change in Control” shall mean an Ownership Change Event or a series of
related Ownership Change Events (collectively, the “Transaction”) wherein the stockholders of the Company immediately before the Transaction do not retain immediately after the Transaction, in substantially
the same proportions as their ownership of shares of the Company’s voting stock immediately before the Transaction, direct or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting power of the
outstanding voting securities of the Company or, in the case of a Transaction described in Section 14.1(a)(iii), the corporation or other business entity to which the assets of the Company were transferred
(the “Transferee”), as the case may be. For purposes of the preceding sentence, indirect beneficial ownership shall include, without limitation, an interest resulting from ownership of the voting securities
of one or more corporations or other business entities which own the Company or the Transferee, as the case may be, either directly or through one or more subsidiary corporations or other business entities. The Board shall have the right to
determine whether multiple sales or exchanges of the voting securities of the Company or multiple Ownership Change Events are related, and its determination shall be final, binding and conclusive. 

14.2    Effect of Change in Control on Purchase Rights. In the
event of a Change in Control, the surviving, continuing, successor, or purchasing corporation or parent thereof, as the case may be (the “Acquiring Corporation”), may, without the consent of any
Participant, assume the Company’s rights and obligations under the Plan. If the Acquiring Corporation elects not to assume the Company’s rights and obligations under the Plan, the Purchase Date of the then current Offering Period shall be
accelerated to a date before the date of the Change in Control specified by the Board, but the number of shares of Stock subject to outstanding Purchase Rights shall not be adjusted. All Purchase Rights which are neither assumed by the Acquiring
Corporation in connection with the Change in Control nor exercised as of the date of the Change in Control shall terminate and cease to be outstanding effective as of the date of the Change in Control. 

15.    NONTRANSFERABILITY OF 
PURCHASE RIGHTS. 
 Neither Contributions or other amounts
credited to a Participant’s Plan account nor a Participant’s Purchase Right may be assigned, transferred, pledged or otherwise disposed of in any manner other than by will or the laws of descent and distribution. Any such attempted
assignment, transfer, pledge or other disposition shall be without effect, except that the Company may treat such act as an election to withdraw from the Plan as provided in Section 12.1. A Purchase Right shall be exercisable during the
lifetime of the Participant only by the Participant. 

16.    COMPLIANCE WITH 
LAW. 
 The issuance of shares under the Plan shall be subject to compliance with all
applicable requirements of federal, state and foreign law with respect to such securities, including the requirements of any securities exchange or market system upon which the Stock may then be listed. A Purchase Right may not be exercised if the
issuance of shares upon such exercise would constitute a violation of any applicable federal, state or foreign securities laws or other law or regulations or the requirements of any securities exchange or market system upon which the Stock may then
be listed. In addition, no Purchase Right may be exercised unless (a) a registration statement under the Securities Act of 1933, as amended, shall at the time of exercise of the Purchase Right be in effect with respect to the shares issuable
upon exercise of the Purchase Right, or (b) in the opinion of legal counsel 

  
 10 

Table of Contents

 
to the Company, the shares issuable upon exercise of the Purchase Right may be issued in accordance with the terms of an applicable exemption from the registration requirements of said Act. The
inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company’s legal counsel to be necessary to the lawful issuance and sale of any shares under the Plan, or the approval of any
securities exchange or market system upon which the Stock may then be listed, if any, deemed by the Company’s legal counsel to be necessary to the issuance and sale of any shares under the Plan in compliance with the requirements of such
securities exchange or market system, shall relieve the Company of any liability in respect of the failure to issue or sell such shares as to which such requisite authority or approval shall not have been obtained. As a condition to the exercise of
a Purchase Right, the Company may require the Participant to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation, and to make any representation or warranty with respect
thereto as may be requested by the Company. 

17.    RIGHTS AS A
STOCKHOLDER AND EMPLOYEE. 
 A Participant
shall have no rights as a stockholder by virtue of the Participant’s participation in the Plan until the date of the issuance of the shares purchased pursuant to the exercise of the Participant’s Purchase Right (as evidenced by the
appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). No adjustment shall be made for dividends, distributions or other rights for which the record date is prior to the date such shares are issued,
except as provided in Section 4.2. Nothing herein shall confer upon a Participant any right to continue in the employ of the Participating Company Group or interfere in any way with any right of the Participating Company Group to terminate the
Participant’s employment at any time. 

18.    LEGENDS. 

The Company may at any time place legends or other identifying symbols referencing any applicable federal, state or foreign securities law restrictions
or any provision convenient in the administration of the Plan on some or all of the certificates representing shares of Stock issued under the Plan. The Participant shall, at the request of the Company, promptly present to the Company any and all
certificates representing shares acquired pursuant to a Purchase Right in the possession of the Participant in order to carry out the provisions of this Section. Unless otherwise specified by the Company, legends placed on such certificates may
include but shall not be limited to the following: 
 “THE SHARES EVIDENCED BY THIS CERTIFICATE WERE ISSUED BY THE CORPORATION TO THE REGISTERED HOLDER UPON THE
PURCHASE OF SHARES UNDER AN EMPLOYEE STOCK PURCHASE PLAN AS DEFINED IN SECTION 423 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED. THE TRANSFER AGENT FOR THE SHARES EVIDENCED HEREBY SHALL NOTIFY THE CORPORATION IMMEDIATELY OF ANY TRANSFER OF
THE SHARES BY THE REGISTERED HOLDER HEREOF. THE REGISTERED HOLDER SHALL HOLD ALL SHARES PURCHASED UNDER THE PLAN IN THE REGISTERED HOLDER’S NAME (AND NOT IN THE NAME OF ANY NOMINEE).” 

19.    NOTIFICATION OF DISPOSITION 
OF SHARES. 
 The Company may require the Participant to give the
Company prompt notice of any disposition of shares acquired by exercise of a Purchase Right. The Company may require that until such time as a Participant disposes of shares acquired upon exercise of a Purchase Right, the Participant shall hold all
such shares in the Participant’s name (or, if elected by the Participant, in the name of the Participant and his or her spouse but not in the name of any nominee) until the later of two years after the date of grant of such Purchase Right or
one year after the date of exercise of such Purchase Right. The Company may direct that the certificates evidencing shares acquired by exercise of a Purchase Right refer to such requirement to give prompt notice of disposition. 

20.    NOTICES. 

All notices or other communications by a Participant to the Company under or in connection with the Plan shall be deemed to have been duly given when
received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof. 
 
21.    CODE SECTION 409A. 
 The Section 423(b) Plan is
exempt from the application of Section 409A of the Code. The Non-Section 423(b) Plan is intended to be exempt from the application of Section 409A of the Code under the short-term
deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent. Except as provided in Section 22, in the case of a Participant who would otherwise be subject to Section 409A of the Code, to the
extent the Board determines that a Purchase Right or the exercise, payment, settlement or deferral thereof is subject to Section 409A of the Code, the Purchase Right shall be granted, exercised, paid, settled or deferred in a manner that will
comply with Section 409A of the Code, including U.S. Treasury Regulations promulgated thereunder (and other Internal Revenue Service guidance) and any ambiguities shall be construed and interpreted in accordance with such intent. Anything in
the foregoing to the contrary notwithstanding, the Company shall have no liability to a Participant or any other party if the Purchase Right that is intended to be exempt from or compliant with Section 409A of the Code is not so exempt or
compliant or for any action taken by the Board with respect thereto. 

  
 11 

Table of Contents

22.    TAX-QUALIFICATION. 

Although the Company may endeavor to (a) qualify a Purchase Right for favorable tax treatment under the laws of the United States or jurisdictions
outside of the United States or (b) avoid adverse tax treatment (e.g., under Section 409A of the Code), the Company makes no representation to that effect and expressly disavows any covenant to maintain favorable or avoid unfavorable tax
treatment, anything to the contrary in this Plan, including Section 21, notwithstanding. The Company shall be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants under the Plan. 

23.    AUTOMATIC TRANSFER TO 
LOW PRICE OFFERING PERIOD. 

To the extent permitted by Applicable Laws, if the Fair Market Value of the Stock on any Purchase Date in an Offering Period is lower than the Fair
Market Value of the Stock on the Offering Date of such Offering Period, then all Participants in such Offering Period, excluding those Participants who have decreased their rate of Contributions to zero percent (0%) during such Offering Period
pursuant to Section 10.3, will be automatically withdrawn from such Offering Period immediately after the exercise of their Purchase Right on such Purchase Date and automatically re-enrolled in
the immediately following Offering Period (including an Offering Period beginning the same day) as of the first day thereof. 
 
24.    AMENDMENT OR TERMINATION OF THE PLAN. 

24.1    The Board may at any time and for any reason amend, suspend or terminate the Plan, or any part thereof, except that
(a) no such amendment shall affect Purchase Rights previously granted under the Plan unless expressly provided by the Board and (b) no such amendment may adversely affect a Purchase Right previously granted under the Plan without the
consent of the Participant, except to the extent permitted by the Plan or as may be necessary to qualify the Section 423(b) Plan as an employee stock purchase plan pursuant to Section 423 of the Code or to comply with any applicable law,
regulation or rule. If the Plan is terminated, the Board, in its discretion, may elect to terminate all outstanding Offering Periods either immediately or upon completion of the purchase of shares of Stock on the next Purchase Date (which may be
sooner than originally scheduled, if determined by the Board in its discretion), or may elect to permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to Section 4.2 and/or Section 14). If
the Offering Periods are terminated prior to expiration, all amounts then credited to Participants’ accounts that have not been used to purchase shares of Stock will be returned to the Participants (without interest thereon, except as otherwise
required under Applicable Laws, as further set forth in Section 10.7 hereof) as soon as administratively practicable. In addition, an amendment to the Plan must be approved by the stockholders of the Company within twelve (12) months of
the adoption of such amendment if such amendment would authorize the sale of more shares than are then authorized for issuance under the Plan or would change the definition of the corporations that may be designated by the Board as Participating
Companies. 
 24.2    Notwithstanding the foregoing, in the event that the Board determines that continuation of the Plan or an
Offering would result in unfavorable financial accounting consequences to the Company, the Board may, in its discretion and without the consent of any Participant, including with respect to an Offering Period then in progress: (a) terminate the
Plan or any Offering Period, (b) accelerate the Purchase Date of any Purchase Period or Offering Period, (c) reduce the discount applicable in determining the Purchase Price of any Offering Period, (d) amend the Plan to conform with
the safe harbor definition under the Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto), (e) alter the Purchase Price for any Offering Period or Purchase Period, (f) reduce the
maximum number of shares of Stock that may be purchased in any Offering Period, (g) reduce the maximum percentage of Compensation a Participant may elect to set aside as Contributions or (e) take any combination of the foregoing actions.

 25.    MISCELLANEOUS. 

25.1    Governing Law. The Plan shall be governed by, and construed in accordance with, the laws of the State of California
(except its choice-of-law provisions). 

25.2    Severability. If any provision of the Plan is or becomes or is deemed to be invalid, illegal, or unenforceable for
any reason in any jurisdiction or as to any Participant, such invalidity, illegality or unenforceability shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as to such jurisdiction or Participant as if the
invalid, illegal or unenforceable provision had not been included. 

  
 12 

Table of Contents

 APPENDIX A 

FORMS OF 
 SUBSCRIPTION AGREEMENT 

AND 
 NOTICE OF WITHDRAWAL 

  
 13 

Table of Contents

 SALESFORCE.COM, INC. 

2004 EMPLOYEE STOCK PURCHASE PLAN 
 SUBSCRIPTION
AGREEMENT 
  

							
	NAME (Please print):	 	 	  	 	  	 
		 	(Last)	  	(First)	  	(Middle)

							
	
	TM    Original application for the Offering Period beginning (date):     
                                         
                                         
                                 
	
	TM     Change in payroll deduction rate effective with the pay period beginning
(date):                                        
                                        

	
	TM     Stop payroll deductions effective with the pay period beginning
(date):                                        
                                         
             

  

	I.	 SUBSCRIPTION 

I elect to participate in the 2004 Employee Stock Purchase Plan (the “Plan”) of salesforce.com, inc. (the “Company”) and
to subscribe to purchase shares of the Company’s Stock in accordance with this Subscription Agreement, including the Additional Terms and Conditions of Participation set forth in an addendum hereto (the “Addendum”), and the
Plan. 
 I authorize payroll deductions of        percent (in whole percentages not less than 2%, unless an
election to stop deductions is being made, or more than 15%) of my Compensation on each pay day throughout the Offering Period in accordance with the Plan. I understand that these payroll deductions will be
accumulated for the purchase of shares of Stock at the applicable purchase price determined in accordance with the Plan. Except as otherwise provided by the Plan, I will automatically purchase shares on each Purchase Date unless I
withdraw from the Plan by giving written notice on a form provided by the Company or unless my eligibility or employment terminates. 
 I understand
that I will not be able to increase my contribution percentage above during a Purchase Period or Offering Period, and that I may only decrease my contribution percentage once per Purchase Period. 

I understand that I will automatically participate in each subsequent Offering that commences immediately after the last day of an Offering in which I am
participating until I withdraw from the Plan by giving written notice on a form provided by the Company or my eligibility or employment terminates. 

I agree to make adequate provision for the federal, state, local and foreign tax withholding obligations, if any, which arise upon my purchase of shares
under the Plan and/or my disposition of shares. The Company may withhold from my compensation the amount necessary to meet such withholding obligations, or using any other method specified in the Addendum. 

I agree that, unless otherwise permitted by the Company, until I dispose of shares I purchase under the Plan, I will hold such shares in the name(s)
entered above (and not in the name of any nominee) until the later of (i) two years after the first day of the Offering Period in which I purchased the shares and (ii) one year after the Purchase Date on which I purchased the shares. This
restriction only applies to the name(s) in which shares are held and does not affect my ability to dispose of Plan shares. 
 I agree
that I will notify the Global Equity Plan Services Group of the Company in writing within 30 days after any sale, gift, transfer or other disposition of any kind prior to the end of the periods referred to in the preceding paragraph (a
“Disqualifying Disposition”) of any shares I purchased under the Plan. If I do not respond within 30 days of the date of a Disqualifying Disposition Survey delivered to me by certified mail, the Company is authorized to treat my
nonresponse as my notice to the Company of a Disqualifying Disposition and to compute and report to the Internal Revenue Service the ordinary income I must recognize upon such Disqualifying Disposition. 

 

	II.	 PARTICIPANT DECLARATION 

Any election I have made on this form revokes all prior elections with regard to this form. 

I am familiar with the provisions of the Plan and agree to participate in the Plan subject to all of its provisions and subject to the Additional Terms
and Conditions of Participation set forth in the Addendum to this Subscription Agreement. I understand that the Board of Directors of the Company reserves the right to terminate the Plan or to amend the Plan and my right to purchase stock under the
Plan to the extent provided by the Plan or the Addendum. I understand that the effectiveness of this Subscription Agreement is dependent upon my eligibility to participate in the Plan. 

 

					
	Date:                                     
                                	  		 	 
		  		 	Signature of Participant

  
 14 

Table of Contents

 SALESFORCE.COM, INC. 

2004 EMPLOYEE STOCK PURCHASE PLAN 
 NOTICE OF
WITHDRAWAL 
  

							
	NAME (Please print):	 	 	  	 	  	 
		 	(Last)	  	(First)	  	(Middle)

 I elect to withdraw from the salesforce.com, inc. 2004 Employee Stock Purchase Plan (the “Plan”) and the
Offering which began on (date)              and in which I am participating (the “Current Offering”). 

I understand that I am terminating immediately my interest in the Plan and the Current Offering, and that no further payroll deductions will be made
(provided I have given sufficient notice before the next pay day). My payroll deductions not previously used to purchase shares will not be used to purchase shares in the Current Offering, but instead will be paid to me as soon as
practicable. I understand that I will not participate in the Plan unless I elect to become a participant in another Offering by filing a new Subscription Agreement with the Company. I understand that I will receive no interest on the amounts paid to
me from my Plan account, and that I may not apply such amounts to any other Offering under the Plan or any other employee stock purchase plan of the Company. 
  

					
	Date:                                     
                        	  	Signature: 	  	 
		  		  	

  
 15 

Table of Contents

 TABLE OF CONTENTS 

 
  
  

							
	 	 	  
	  	Page	 
	 1.
	 	Establishment, Purpose and Term of Plan	  	 	1	 
		 	1.1         Establishment	  	 	1	 
		 	1.2         Purpose	  	 	1	 
		 	1.3         Term of Plan	  	 	1	 
			
	 2.
	 	Definitions and Construction	  	 	1	 
		 	2.1         Definitions	  	 	1	 
		 	2.2         Construction	  	 	3	 
			
	 3.
	 	Administration	  	 	3	 
		 	3.1         Administration by the Board	  	 	3	 
		 	3.2         Authority of Officers	  	 	4	 
		 	3.3         Policies and Procedures Established by the Company	  	 	4	 
		 	3.4         Indemnification	  	 	4	 
			
	 4.
	 	Shares Subject to Plan	  	 	4	 
		 	4.1         Maximum Number of Shares Issuable	  	 	4	 
		 	4.2         Adjustments for Changes in Capital Structure	  	 	5	 
			
	 5.
	 	Eligibility	  	 	5	 
		 	5.1         Employees Eligible to Participate	  	 	5	 
		 	5.2         Exclusion of Certain Stockholders	  	 	5	 
		 	5.3         Determination by Company	  	 	6	 
			
	 6.
	 	Offerings	  	 	6	 
			
	 7.
	 	Participation in the Plan	  	 	6	 
		 	7.1         Initial Participation	  	 	6	 
		 	7.2         Continued Participation	  	 	6	 
			
	 8.
	 	Right to Purchase Shares	  	 	6	 
		 	8.1         Grant of Purchase Right	  	 	6	 
		 	8.2         Calendar Year Purchase Limitation	  	 	7	 
			
	 9.
	 	Purchase Price	  	 	7	 
			
	 10.
	 	Accumulation of Purchase Price through Payroll Deduction	  	 	7	 
		 	10.1       Amount of Payroll Deductions	  	 	7	 
		 	10.2       Commencement of Contributions	  	 	7	 
		 	10.3       Election to Change or Stop Contributions	  	 	7	 
		 	10.4       Alternative Contributions	  	 	8	 
		 	10.5       Administrative Suspension of Contribution	  	 	8	 
		 	10.6       Participant Accounts	  	 	8	 
		 	10.7       No Interest Paid	  	 	8	 
			
	 11.
	 	Purchase of Shares	  	 	8	 
		 	 11.1       Exercise of Purchase Right
	  	 	8	 
		 	 11.2       Pro Rata Allocation of
Shares
	  	 	8	 
		 	 11.3       Delivery of Certificates
	  	 	9	 
		 	 11.4       Return of Cash Balance
	  	 	9	 
		 	 11.5       Tax Withholding
	  	 	9	 
		 	 11.6       Expiration of Purchase
Right
	  	 	9	 
		 	 11.7      
 Provision of Reports and Stockholder Information to Participants
	  	 	9	 
			
	 12.
	 	Withdrawal from Plan	  	 	9	 
		 	 12.1       Voluntary Withdrawal from the
Plan
	  	 	9	 
		 	 12.2       Return of Payroll
Deductions
	  	 	9	 
			
	 13.
	 	Termination of Employment or Eligibility	  	 	10	 
			
	 14.
	 	Change in Control	  	 	10	 
		 	 14.1       Definitions
	  	 	10	 
		 	 14.2      
 Effect of Change in Control on Purchase Rights
	  	 	10	 
			
	 15.
	 	Nontransferability of Purchase Rights	  	 	10	 

  
 16 

Table of Contents

							
	 	 	  
	  	Page	 
	 16.
	 	Compliance with Law	  	 	10	 
			
	 17.
	 	Rights as a Stockholder and Employee	  	 	11	 
			
	 18.
	 	Legends	  	 	11	 
			
	 19.
	 	Notification of Disposition of Shares	  	 	11	 
			
	 20.
	 	Notices	  	 	11	 
			
	 21.
	 	Code Section 409A	  	 	11	 
			
	 22.
	 	Tax Qualification	  	 	12	 
			
	 23.
	 	Automatic Transfer to Low Price Offering Period	  	 	12	 
			
	 24.
	 	Amendment or Termination of the Plan	  	 	12	 
			
	 25.
	 	Miscellaneous	  	 	12	 

  
 17Exhibit 10.4

 

FINAL

Supply
Agreement

 

This Supply Agreement
(the “Agreement”) is made, effective as of June 9, 2020 (the “Effective Date”) by and between
BryoLogyx Inc. (“BryoLogyx”) and Neurotrope Bioscience, Inc. (“Neurotrope”), each of Neurotrope
and BryoLogyx being referred to herein individually as a “Party” and collectively as the “Parties,”
with respect to the supply by BryoLogyx to Neurotrope of cGMP synthetic bryostatin-1 under the terms and conditions set forth herein.

 

BACKGROUND

 

		A.	Neurotrope is a clinical-stage biotech company leveraging bryostatin-1
and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders, and
is a party to that certain Cooperative Research And Development Agreement with the U.S. Department of Health and Human Services,
as represented by National Cancer Institute of the NIH dated January 29, 2019 (the “CRADA”) under which Neurotrope
would study bryostatin-1 in its application to cancer therapy using Neurotrope’s inventory of naturally derived bryostatin-1.

 

		B.	BryoLogyx is a clinical-stage biotech company currently dedicated
to developing drugs to enhance the response rates and treatment durability of cancer immunotherapies, and has developed a method
of manufacturing synthetic bryostatin-1 pursuant to the process invented by Dr. Paul Wender at Stanford University (“the
Wender Process”). Stanford University owns the rights to the Wender Process and has licensed BryoLogyx to use, and manufacture
for its use, the Wender Process for the development of drugs for cancer treatments.

 

		C.	Neurotrope is also licensed by Stanford University to use the Wender Process for the treatment
of neurological or neurodegenerative diseases.

 

		D.	The Parties have entered into that certain Transfer Agreement of even date herewith pursuant to
which Neurotrope will transfer the CRADA to BryoLogyx, and will assign Neurotrope’s IND PIND140578 to BryoLogyx, all in furtherance
of BryoLogyx’s own clinical development program, in exchange for a revenue share.

 

		E.	Neurotrope would like to source synthetic bryostatin-1 from BryoLogyx, and BryoLogyx is willing
to supply such material to Neurotrope, all as set forth in more detail herein.

 

		F.	It is the intent and agreement of the Parties that this Agreement and the above referenced Transfer
Agreement together constitute the entire agreement of the Parties with respect to the matters governed thereby.

 

1.             Definitions and Interpretation

 

1.1              
Definitions. The terms in this Agreement with initial letters capitalized, whether used in the singular or the plural, will
have the meaning for such relevant term set forth below or, if not listed below, the meaning designated elsewhere in this Agreement.

 

(a)   
 “Additional Order” has the meaning set forth therefor in Section 2.4 hereof.

 

(b)   
 “API” means cGMP synthetic bryostatin-1 as an active pharmaceutical ingredient to be used in a drug product,
and meeting the Specifications, and named in the Quality Agreement.

 

(c)   
 “Applicable Requirements” means (a) all requirements of the Quality Agreement, (b) the Useful Life requirement
(which condition will not apply to the Initial Order), and (c) all applicable international, supranational, multinational, federal,
regional, state, provincial and local laws, ordinances, rules and regulations of any governmental authority that apply to API or
the Processing of API or this Agreement, including (i) all applicable laws, ordinances, rules and regulations of the jurisdiction
where the Facility is located; (ii) cGMP; (iii) Regulatory Agencies’ regulations and guidelines; and (iv) those pertaining
to workplace health and safety, all as may be amended from time to time.

 

     

     

    

BryoLogyx/Neurotrope—Bryostatin-1
Supply Agreement

 

(d)   
““bryostatin-1” means a macrocyclic lactone
and a potent activator of protein kinase C (PKC) either isolated
from the bryozoan Bugula Neritina or chemically synthesized.

 

(e)   
“business day” means a day on which national banks in the United States are open in New York, New York.

 

(f)    
 “cGMP” means those practices in the manufacture of pharmaceutical products that are recognized as current good
manufacturing practice regulations and guidelines as described and promulgated by Regulatory Authorities including (i) the FDA
in accordance with FDA regulations guidelines and other administrative interpretations, and, without limitation, (ii) the then-current
International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q7 Good
Manufacturing Practice Guidance for Active Pharmaceutical Ingredients as adopted by the relevant Regulatory Authority in the subject
jurisdiction, and (iii) The European Union’s Eudralex Volume 4,

Part II (independent of the Annexes) where it is in direct agreement with ICH Q7, all as updated, amended, and revised from time
to time.

 

(g)   
 “COGS” means BryoLogyx’s fully-burdened cost of all direct materials and labor and

fully-allocated manufacturing overhead directly attributable to the cost of process development and validation and the Processing
of API for Neurotrope hereunder, calculated in accordance with US GAAP, consistently applied; provided, that manufacturing overhead
will not include allocation of idle capacity.

 

(h)   
 “Confidential Information” will have the meaning set forth in Section 8 hereof.

 

(i)    
 “Defect” or “Defective” means a unit of API that does not conform to the Specifications or
was not Processed in accordance with Applicable Requirements or does not meet the Useful Life, provided that such Useful Life requirement
in order for API to not be Defective will apply only to Additional Orders and not to the Initial Order.

 

(j)    
 “Deficiency Notice” means a written notice from Neurotrope to BryoLogyx claiming a Defect with respect to API,
and/or shortages in the amount of delivered API, and describing in reasonable detail such Defect or shortage.

 

(k)   
 “Dollar” or “$” means the lawful currency of the United States.

 

(l)    
 “FDA” means the U.S. Food and Drug Administration, or any successor agency thereto having jurisdiction over
the manufacture of the API.

 

(m)  “Initial
Order” has the meaning therefor set forth in Section 2.2 hereof.

 

(n)   
 “Intellectual Property” means any right or protection existing from time to time in a specific jurisdiction,
whether registered or not, under any patent law or other invention or discovery law, copyright law, trade-secret law, trademark
law or trade name law, and includes legislation by competent governmental authorities and judicial decisions under common law or
equity.

 

(o)   
 “Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association,
joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority or
any other form of entity not specifically listed herein.

 

(p)      
 “Processing” means all steps and activities to be performed for the manufacture, storage and delivery of API
for supply by BryoLogyx to Neurotrope pursuant to this Agreement.

 

    	 	2	 

    	BryoLogyx/Neurotrope—Bryostatin-1 Supply Agreement

    

 

(q)      
 “Quality Agreement” means a separate written agreement that has been entered into between BryoLogyx and BryoLogyx’s
contract manufacturer for the API that describes the quality assurance and technical requirements for Processing, a copy of which
will be provided to Neurotrope as promptly as possible when the Quality Agreement has been updated for the cGMP synthetic processing
of bryostatin-1, which Quality Agreement, when so furnished, will be deemed confidential and will thus be subject to the confidentiality
provisions of Section 8 hereof.

 

(r)       
 “Regulatory Agency” means any national, federal, state or local or other regulatory agency, department, bureau
or other governmental entity (including the FDA) which is responsible for issuing approvals, licenses, registrations or authorizations
necessary for the manufacture, import, distribution, sale and use of API.

 

(s)    
 “Specifications” means the specifications for API as set forth in Exhibit A attached hereto and incorporated
herein by reference, as such Exhibit may be amended from time to time by the Parties in writing in accordance with the terms of
this Agreement.

 

(t)    
 “Supply Period” means the period of time commencing with the date of cGMP certification and Neurotrope’s
acceptance of the initial production run of synthetic bryostatin-1 produced by BryoLogyx under a license to BryoLogyx from Stanford
University, and ending upon the earlier of (i) the fifth (5th) annual anniversary of the date of completion by Neurotrope
of Phase 3clinical trials using API, provided that Neurotrope will promptly inform BryoLogyx in writing of the date of completion
of such Phase 3 clinical trials, or (ii) such earlier or later date as is agreed by the Parties in writing in accordance with the
terms of this Agreement.

 

(u)   
 “Term” means the Supply Period.

 

(v)   
 “Third Party” means any Person other than Neurotrope or BryoLogyx.

 

(w)  “UNCISG”
means the United Nations Convention on Contracts for the International Sale
of Goods, as in effect from time to time.

 

(x)   
 “Unit Price” Means the price per gram of API which is equal to COGS of such gram of API plus 15%, in each case
calculated as at the time of production of the API requested by Neurotrope under the Initial Order or under the relevant Additional
Order.

 

(y)   
 “Useful Life” means the time period within which API will remain stable after the date of BryoLogyx’s
release of the relevant lot of API to Neurotrope, which BryoLogyx expects to be at least twenty-four (24) months, with the Parties
acknowledging, however, that the Useful Life of API is not known or confirmed as at the Effective Date and thus will not be an
applicable requirement as to API in the Initial Order, provided, however, that BryoLogyx will use its commercially diligent efforts,
in working with its contract manufacturer of API, to determine and confirm Useful Life for API, and will promptly communicate such
confirmed Useful Life to Neurotrope in writing as soon as it is confirmed to BryoLogyx, and such confirmed Useful Life thereafter
will be applicable to determining whether API in an Additional Order is Defective or meets the Applicable Requirements.

 

1.2              
Interpretation. The captions and headings to this Agreement are for convenience only, and are to be of no force or effect
in construing or interpreting any of the provisions of this Agreement. Unless specified to the contrary, references to Sections
will refer to the particular Sections of or to this Agreement. Unless the context otherwise clearly requires, whenever used in
this Agreement: (a) the words “include” or “including” will be construed as incorporating, also, “but
not limited to” or “without limitation;” (b) the word “day,” “quarter” or “year”
(and derivatives thereof, e.g., “quarterly”) means a calendar day, calendar quarter or calendar year unless
otherwise specified (and “annual” or “annually” refer to a calendar year); (c) the word “notice”
means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications
contemplated under this Agreement; (d) the word “hereof,” “herein,” “hereby” and derivative
or similar word refers to this Agreement; (e) the word “or” has its inclusive meaning identified with the phrase “and/or;”
(f) provisions that require that a Party or the Parties “agree,” “consent” or “approve” or
the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter
or otherwise; (g) words of any gender include the other gender; and (h) words using the singular or plural number also include
the plural or singular number, respectively.

 

    	 	3	 

    	BryoLogyx/Neurotrope—Bryostatin-1 Supply Agreement

    

 

2.             Supply of API by BryoLogyx to Neurotrope

 

2.1              
Sole Source. Commencing on the date upon which cGMP certification from its contract manufacturer is obtained by BryoLogyx
for production of API provided such date is not later than March 31, 2021 (or such later date as the Parties may agree in writing)
and thereafter during the Term, and as so long as BryoLogyx is able to supply API to Neurotrope in accordance with the terms of
this Agreement and meeting Neurotrope’s volume requirements, the Applicable Requirements, and the Specifications, BryoLogyx
will be the exclusive supplier to Neurotrope, even as to Neurotrope itself, of API.

 

2.2              
Initial Order. The execution and delivery by the parties of this Agreement constitutes Neurotrope’s firm order for
the purchase by Neurotrope and BryoLogyx of a total of one (1) gram of API (the “Initial Order”).

 

2.3              
Delivery Of The Initial Order. The Initial Order will be shipped by BryoLogyx to Neurotrope within sixty (60) days after
the date upon which cGMP certification is obtained by BryoLogyx for production of API. BryoLogyx will notify Neurotrope promptly
in writing of the date that such cGMP approval is obtained. Such delivery will be made by BryoLogyx to such location in the United
States as Neurotrope informs BryoLogyx in writing within thirty (30) days after the Effective Date.

 

2.4              
Additional Orders By Neurotrope For API; Delivery Of Additional Orders. Any orders by Neurotrope for API beyond the Initial
Order (each an “Additional Order”) must be (a) in writing, (b) for not less than one (1) gram of API unless
otherwise agreed in writing by BryoLogyx in accepting the relevant Additional Order and (c) placed by Neurotrope with BryoLogyx
at least six (6) months lead time before the delivery date of such Additional Order desired by Neurotrope, or such shorter period
of time as BryoLogyx may agree in writing with Neurotrope, and provided that as the manufacturing process for API is further developed
after the Effective Date the Parties will discuss with each other in good faith any potential shortening in such lead time that
may be appropriate and any such changes agreed to will be in writing as an amendment to this Agreement. Delivery of each Additional
Order will be made by BryoLogyx in accordance with the terms of the Additional Order to the location to which the Initial Order
was delivered, or to such location in the United States as Neurotrope informs BryoLogyx in writing when placing the Additional
Order.

 

2.5              
Shipment; Title And Risk Of Loss Or Damage; Acceptance; Deficiency Notice;

Latent Defect.

 

(a)               
Shipment. Shipment to Neurotrope of the Initial Order and of Additional Orders will be made using appropriate packaging
and an appropriate carrier and delivery method as determined in each case by Neurotrope. 

 

(b)               
Title and Risk of Loss or Damage. BryoLogyx will, as to the Initial Order and as to Additional Orders, retain title to,
and will carry the risk of loss or of damage to, API until such API is loaded onto the carrier specified by Neurotrope. Title
and risk of loss or of damage to API will, as to the Initial Order and as to Additional Orders, transfer to Neurotrope upon being
loaded on the carrier. 

 

(c)               
Acceptance; Deficiency Notice; Latent Defect. Neurotrope will be deemed to have accepted the Initial Order, and will be
deemed to have accepted any Additional Orders unless it has sent to BryoLogyx a Deficiency Notice with respect to the relevant
shipment of API within thirty (30) days after Neurotrope’s receipt of such API. If a Defect in API could not reasonably be
discovered by Neurotrope within such thirty (30) day period (a “Latent Defect”), then Neurotrope will have the
right to reject such API within ten (10) business days after discovering the Latent Defect during the intended useable life of
API, provided Neurotrope has given written notice, in commercially reasonable detail as to such Latent Defect, to BryoLogyx within
such 10 business day period. Without limiting other remedies available to Neurotrope, BryoLogyx will, at its sole cost and expense,
make up the shortage or replace the rejected API, as applicable, by delivering replacement API to Neurotrope within thirty (30)
days at no extra charge to Neurotrope. Neurotrope’s actual or deemed acceptance of API will not be construed as limiting
any remedies given Neurotrope at law or under this Agreement. Subject to the provisions of this Section 2.5, Neurotrope has the
right to reject and return, at the expense of BryoLogyx and for full credit, any portion of any shipment of API which deviates
from the Specifications or cGMP, without invalidating the remainder of the order. If BryoLogyx does not agree with Neurotrope’s
determination that API is Defective, then the Parties will designate an independent testing laboratory to determine whether the
API is Defective, the findings of which will be binding on the Parties, absent manifest error. All costs and expenses of such laboratory
testing will be borne by the Party whose position is determined to have been in error, or if the laboratory cannot place the cause
of the rejection or defect noticed, then all costs and expenses of such laboratory testing will be borne by the Parties equally.
All rejected API will be disposed of pursuant to Applicable Requirements. BryoLogyx will not subcontract, transfer or delegate
its performance under this Agreement without Neurotrope’s prior written consent.

 

    	 	4	 

    	BryoLogyx/Neurotrope—Bryostatin-1 Supply Agreement

    

 

2.6              
Certain Limitations And Further Conditions. The fulfillment by BryoLogyx of the Initial Order and of any Additional Orders
will be subject to the following conditions in each case:

 

(a)       Cancellation;
Reduction. Neurotrope may not cancel or reduce the amount of API in the Initial Order nor may it cancel or reduce the amount
of API in any Additional Order, unless in each case such cancellation or reduction is agreed to in writing by BryoLogyx (such agreement
not to be unreasonably withheld).

 

(b)       Conditions
For Supply Of API To Neurotrope For Commercial Sale. BryoLogyx’s obligations hereunder to supply API to Neurotrope for
commercial sale will be subject to (i) BryoLogyx having achieved such regulatory approvals, if any, as may be required with respect
to commercial sale of API, and (ii) BryoLogyx having established for itself a commercial-level manufacturing and supply process
therefor.

 

2.7              
Certain Further Limitations On Neurotrope As To Marketing, Offer To Sell Or Selling API. During the period of time during
the Term in which Neurotrope is using API for its clinical research and clinical trials, Neurotrope will not market, offer to sell
or sell API to any Third Party without the prior written consent of BryoLogyx, and during the remainder of the Term with respect
to commercial sales by Neurotrope, Neurotrope will not market, offer to sell or sell API as a standalone product by itself, but
will only market, offer to sell or sell API as a component of a drug product in a licensed clinical application.

 

2.8              
Changes to Specifications. If either BryoLogyx or Neurotrope believes that any Applicable Requirement requires a change
to the Specifications, the Party believing that such change is required will promptly notify the other Party in writing thereof,
in commercially reasonable detail and thereafter the Parties will in good faith discuss such proposed change to the Specifications.
If BryoLogyx and Neurotrope are unable to reach written agreement regarding whether, and to what extent, an amendment to the Specifications
is required, then such dispute will be resolved pursuant to Section 9 of this Agreement.

 

2.9              
Records. BryoLogyx will maintain complete and accurate records developed in the course of its performance under this Agreement
and will maintain such records for the period of time required by Applicable Requirements, and will make such records available
to the FDA and other applicable regulatory bodies. With the direct participation of BryoLogyx, Neurotrope may (a) review, but may
not make copies of, API manufacturing and testing records, and may (b) audit and manufacturing facilities, all to the extent that
BryoLogyx has such rights pursuant to the Quality Agreement. BryoLogyx will, upon the written request of Neurotrope therefor, make
available to the FDA and other applicable regulatory bodies, solely for use by reference in Neurotrope’s regulatory filings,
the CMC section of BryoLogyx’s IND with respect to the API, and the manufacturer’s Drug Master File, and such other
CMC provisions of BryoLogyx’s IND as are reasonably required in support of Neurotrope’s regulatory filings.

 

    	 	5	 

    	BryoLogyx/Neurotrope—Bryostatin-1 Supply Agreement

    

 

2.10          
Exclusivity. During the term hereof, BryoLogyx will not, directly or indirectly, including by authorization, license or
permission, either itself or on behalf of or with another person or entity, research, develop, distribute, commercialize, manufacture,
license, sell, or supply synthetic bryostatin-1 to any party other than Neurotrope as a pharmaceutical ingredient to be used in
the diagnosis, treatment or prevention of neurological or neurodegenerative disease to the extent governed by the License Agreement
between Stanford University and Neurotrope with respect to the field of use rights granted therein to Neurotrope for the use of
synthetic bryostatin-1 in neurological or neurodegenerative disease.

 

3.            PRICING; FREIGHT CHARGES; SALES TAXES; INSURANCE; INVOICING; PAYMENT

 

3.1              
Pricing. Neurotrope will pay to BryoLogyx, in cash, for API ordered by Neurotrope and delivered by BryoLogyx pursuant to
this Agreement at the Unit Price.

 

3.2              
Freight Charges; Sales Taxes; Insurance. Neurotrope will pay freight charges for delivery of API order hereunder to Neurotrope,
and any applicable sales taxes required by law to be charged by BryoLogyx. The cost of any insurance desired by Neurotrope with
respect to any shipment of API hereunder will be borne by Neurotrope, and Neurotrope will arrange for any such insurance that it
so desires.

 

3.3              
Invoicing; Payment. BryoLogyx will invoice Neurotrope upon shipment of API to Neurotrope. Each invoice will set out the
quantity of API which is the subject of the invoice, the Unit Price, and freight/delivery charges and applicable sales tax amounts.
Neurotrope will pay all invoices in accordance the payment method will be specified by BryoLogyx in the relevant invoice, wire
transfer to such account and routing instructions as will be set forth in such invoice, with wiring or other transmission fees
to be paid by Neurotrope, or by check payable to BryoLogyx be sent to the address as indicated by BryoLogyx in such invoice. Neurotrope
will pay all invoiced amounts that are not in good faith disputed by Neurotrope, within thirty (30) days after Neurotrope’s
receipt of the relevant invoice. The Parties will discuss and finalize in good faith promptly any amounts invoiced by BryoLogyx
to Neurotrope that are disputed in all good faith by Neurotrope.

 

4.             REGULATORY AGENCY COMMUNICATIONS

 

Each Party will notify
the other immediately in writing, in commercially reasonable detail, if the notifying Party receives any communication from or
on behalf of a Regulatory Agency with respect to API, including without limitation any notice of any deficiencies noted or otherwise
referenced by any Regulatory Agency with respect to API and/or its manufacture or with respect to any drug product manufactured
from or incorporating API. Reference is hereby made to the provisions of Section 2.9 hereof, with respect to the availability to
FDA and other applicable regulatory bodies solely for use by reference in Neurotrope’s regulatory filings the CMC section
of BryoLogyx’s IND with respect to the API, and the manufacturer’s Drug Master File, and such other CMC provisions
of BryoLogyx’s IND, as are reasonably required in support of Neurotrope’s regulatory filings.

 

5.             Representations and Warranties

 

5.1              
General. Each Party represents and warrants to the other Party that:

 

(a)         
Authority. The representing Party has all corporate or other authority to perform this Agreement and this Agreement has
been duly executed and delivered and constitutes such Party's legal, valid and binding obligation enforceable against it in accordance
with its terms subject, as to enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability relating
to or affecting creditors' rights and to the availability of particular remedies under general equity principles;

 

(b)         
No Action or Proceeding. The representing Party is not involved in any action or proceeding and has not received notice
of any threatened action or proceeding that would jeopardize its performance under this Agreement;

 

    	 	6	 

    	BryoLogyx/Neurotrope—Bryostatin-1 Supply Agreement

    

 

(c)         
The execution, delivery and performance by the representing Party of this Agreement and its compliance with the terms hereof, does
not and will not conflict with or result in a breach of any term of, or constitute a default under (i) any agreement or instrument
binding or affecting it or its property; (ii) its charter documents or bylaws; or (iii) any order, writ, injunction or decree of
any court or governmental authority entered against it or by which any of its property is bound;

 

(d)         
The representing Party has obtained any consent, approval or authorization of, or notice, declaration, filing or registration with,
any governmental or regulatory authority required for the execution, delivery and performance of this Agreement by such Party,
and the execution, delivery and performance of this Agreement will not violate any law, rule or regulation applicable to such Party;
and

 

(e)         
Approvals. The representing Party has obtained all necessary corporate approvals to enter into and execute this Agreement
and to perform such Party’s obligations hereunder.

 

5.2              
Additional Representation by BryoLogyx. In addition to its representations under Section 5.1 hereof, BryoLogyx further represents
and warrants to Neurotrope that BryoLogyx’ method of manufacturing synthetic bryostatin-1 results in a product that is equivalent
in all analytical respects to natural bryostatin-1 as supplied by the NCI and that each unit of API at the time of delivery to
Neurotrope will conform to the Specifications, be free from Defects, fit for such products intended use, properly packaged and
labeled to the extent required by law, and be delivered free from any encumbrances. BryoLogyx represents and certifies that all
persons engaged by it to perform work relating to this Agreement have never been and are not currently debarred pursuant to the
Generic Drug Enforcement Act of 1992, 21 U.S.C. §335(a), as amended, or any similar state law or regulation, excluded by the
Office of Inspector General pursuant to 42 U.S.C. § 1320a-7, et seq. or any state agency from participation in any Federal
or state health care program or otherwise disqualified or restricted by the FDA pursuant to 21 C.F.R. 312.70 or any other regulatory
authority.

 

5.3              
Disclaimer. EXCEPT AS PROVIDED IN THIS SECTION 5, NEITHER PARTY MAKES ANY WARRANTIES,
whether EXPRESS, IMPLIED, or STATUTORY, WITH RESPECT TO THE SUBJECT MATTER HEREOF AND EACH PARTY EXPRESSLY DISCLAIMS ANY SUCH ADDITIONAL
WARRANTIES.

 

6.             Term and Termination

 

6.1              
Term. The Term of this Agreement will commence on the Effective Date and will continue in full force and effect for the
Supply Period unless earlier terminated as provided herein (the “Term”).

 

6.2              
Termination for Cause. Either Party may terminate this Agreement immediately (or in the case of events described in Section
6.2(a) hereof, after the applicable cure period has elapsed) and without prior written notice to the other Party, upon the happening
of any of the following events of default, provided that the terminating Party will provide written notice to the other Party,
after such termination, of such termination and of the effective date thereof, and provided that any termination under this Section
6.2 will be subject to the provisions of Section 6.4 hereof:

 

(a)               
Material Uncured Breach. The other Party materially breaches any obligation, warranty or representation hereunder of such
Party (which will include without limitation, the failure of the Neurotrope to pay any undisputed monies when payable hereunder)
and such breach is not cured within thirty (30) days after written notice thereof from the non-breaching Party, setting forth the
nature of the alleged breach in commercially reasonable detail; or

 

(b)               
Bankruptcy, Etc. The other Party makes a general assignment for the benefit of its creditors, suspends business or commits
any act amounting to business failure, voluntarily assigns or transfers all or substantially all of its property, files a voluntary
petition or has an involuntary petition filed against it seeking its reorganization, adjustment, liquidation, or dissolution under
any present or future law or regulation relating to bankruptcy, which petition is not dismissed within 90 days, insolvency, relief
of debtors or protection of creditors, termination of legal entities, or has a receiver, trustee, liquidator, assignee or custodian
appointed for it.

 

    	 	7	 

    	BryoLogyx/Neurotrope—Bryostatin-1 Supply Agreement

    

 

(c)               
cGMP. BryoLogyx is unable to obtain cGMP certification from its contract manufacturer by March 31, 2021 and the Parties
are unable to agree in writing to a later date as set forth in Section 2.1.

 

6.3              
Termination for Convenience. Until the date that Neurotrope places its first Additional Order for commercial supply of API,
Neurotrope may not terminate this Agreement, other than for the reasons set forth in Section 6.2 hereof. After the date upon which
Neurotrope places its first Additional Order for commercial supply of API, either Party may terminate this Agreement for any reason
or no reason upon at least six (6) months’ prior written notice to the other Party, subject to the provisions of Section
6.2 hereof. Any termination under this Section 6.3 will be subject to the provisions of Section 6.4 hereof.

 

6.4              
Effect of Termination.

 

(a)               
Fulfillment Of Certain Obligations. Upon any termination of this Agreement, both Parties will fully perform all of their
obligations hereunder that have accrued through the date of such termination.

 

(b)               
Shipment Of API By BryoLogyx To Neurotrope. Upon the effective date of termination of this Agreement by either party, then,
unless the Parties agree otherwise in writing, BryoLogyx will deliver to Neurotrope all API in inventory or storage, with respect
to the Initial Order and each Additional Order, and Neurotrope will be required to pay for such API under the terms for payment
set forth in this Agreement.

 

(c)               
Transition Assistance. If Neurotrope terminates this Agreement pursuant to Section 6.2(b) hereof, then BryoLogyx will, at
Neurotrope’s written request, promptly and diligently work with AMRI (formerly known as Albany Molecular Research Inc.; “AMRI”)
to cause AMRI to provide API directly to Neurotrope under such terms as set forth in the agreement between BryoLogyx and AMRI until
AMRI and Neurotrope enter into their own separate written agreement for such supply, provided that Neurotrope will pay AMRI directly
for supply of API by AMRI to Neurotrope. BryoLogyx acknowledges that time is of the essence in BryoLogyx’s performance of
this Section 6.4(c) and will use its commercially diligent efforts to facilitate the transition to AMRI of API supply to Neurotrope.

 

6.5              
Survival. Notwithstanding anything herein to the contrary, termination of this Agreement by a Party will be without prejudice
to other remedies such Party may have at law or equity. Sections

1, 2.8, 4, 6.4, 6.5, 7, 8, 9 and 10 hereof, and all liabilities that accrue during the Term, will survive expiration or termination
of this Agreement and will continue to be enforceable.

 

7.            Intellectual Property Rights

 

Each Party will retain,
and no license or other right is granted to the other Party with respect to, such first Party’s intellectual property rights,
however arising, including any intellectual property rights of the relevant Party which may arise after the Effective Date, and
including without limitation any such intellectual property rights with respect to bryostatin in any form or formulation, and further
provided that the Parties do not intend to conduct with each other during the Term any research and development activities related
to bryostatin in any form or formulation and that any such collaborative activities will be the required to be set forth in and
governed by a separate written agreement between the Parties with respect thereto.

 

    	 	8	 

    	BryoLogyx/Neurotrope—Bryostatin-1 Supply Agreement

    

 

8.            Confidentiality

 

8.1              
Confidentiality. The Parties are parties to that certain Mutual Confidentiality Agreement dated as of April 13, 2018 (the
 “CDA”). BryoLogyx and Neurotrope each acknowledge and agree that they have been and will be in a confidential
relationship to the other Party pursuant to this Agreement and that each has gained and will gain knowledge that comprises valuable
trade secrets and other confidential information of the other Party, including customer lists, other customer data and information,
sales and marketing data and information, technical data and information, Processing information, Intellectual Property, and other
data and information concerning API, including the Specifications, or the Party’s respective businesses, all of which, including
without limitation the Quality Agreement as confidential information of BryoLogyx, constitutes confidential information of the
relevant Party under the CDA, and the Parties’ use of such information will be governed by the CDA and this Agreement.

 

8.2              
Public Announcements. Neither Party will advertise, issue any press release, post any image or make any other public statement,
including without limitation any disclosure requirements of Neurotrope under applicable securities laws, regarding or relating
to the Parties’ relationship pursuant to this Agreement, including the terms and conditions of this Agreement, without the
other Party’s express prior written approval, which will not be unreasonably or untimely withheld or denied.

 

9.           DISPUTE RESOLUTION.

 

Any claim arising
out of or relating to this Agreement or the validity, enforcement, or breach thereof, will be first referred by either Party, in
writing to the other Party, simultaneously to the President or Chief Executive Officer the other Party, which individuals will
promptly and in good faith discuss and attempt to resolve such matter, including in such discussion the possibility of mediation
or arbitration, provided that if after such good faith discussion the matter is not successfully resolved, each Party will have
the right to pursue such judicial remedy or remedies as are available to it.

 

10.         Miscellaneous

 

10.1          
Limitation of Liability. IN NO EVENT WILL EITHER PARTY BE LIABLE FOR LOSS OF PROFITS, LOSS OF REVENUE OR INCOME, LOSS OF
BUSINESS REPUTATION OR OPPORTUNITY, OR OTHER INDIRECT, INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES UNDER THIS AGREEMENT, EXCEPT
FOR DAMAGES CAUSED BY (A) A BREACH OF SECTION 8 (CONFIDENTIALITY) HEREOF, OR (B) A PARTY’S GROSS NEGLIGENCE, MISCONDUCT OR
VIOLATION OF LAW, OR (C) BRYOLOGYX’S BREACH OF SECTION 2.10 HEREOF.

 

10.2          
Governing Law. This Agreement and all actions arising out of or in connection with this Agreement will be governed by and
construed in accordance with the laws of the State of California, without regard to the conflict of laws provisions thereof or
of any other state and provided that the UNCISG will not apply to this Agreement.

 

10.3          
Independent Contractors. The relationship between Neurotrope and BryoLogyx hereunder will be that of independent contractors,
and nothing in this Agreement will be deemed to constitute a joint venture, partnership, agency or employer/employee arrangement
between the Parties. Neither Party will have any authority or power to bind the other Party or to contract in the name of, or make
any representations or warranties, express or implied, on behalf of the other Party, or otherwise create any liability against
the other Party in any way for any purpose.

 

10.4          
Force Majeure. The Parties hereto will not be responsible for any loss or breach due to delay in delivery or performance
hereunder caused by causes outside of such Party’s reasonable control which may include governmental regulations, controls
or directions, outbreak of a state of emergency, hostilities, civil commotion, riots, epidemics, acts of God, other natural casualties,
fires, strikes, or walkouts or other similar unforeseeable cause or causes not caused by the affected Party’s negligence.
In the event that any Party will be delayed in, or prevented from, performing its obligations under this Agreement as a result
of any of the foregoing, such Party will promptly notify the other Party of such delay or cessation in performance. In the event
that such Party is unable to resume performance hereunder within sixty (60) days after the date on which its performance was suspended,
the other Party will have the right to terminate this Agreement upon at least ten (10) days prior written notice to the non-performing
Party.

 

10.5          
Assignment. Neither Party may assign this Agreement without the prior written consent of the other Party, which consent
will not be unreasonably withheld, delayed or conditioned; provided, however, that each Party may assign this Agreement without
the consent of the other Party to a successor to all or substantially all of such Party’s business or assets relating to
this Agreement whether by sale, amalgamation, merger, operation of law or otherwise. The Party assigning this Agreement will notify
the other Party in writing promptly (but in no event more than ten (10) days) after such assignment, which notice will include
the name and address of the assignee, and provided that it will be a condition of any such assignment that the assignee agrees
in writing specifically for the benefit of the non-assigning Party to fully assume and discharge the remaining undischarged obligations
of the assigning Party. Any assignment in violation of this Section 10.5 will be null and void.

 

    	 	9	 

    	BryoLogyx/Neurotrope—Bryostatin-1 Supply Agreement

    

 

10.6          
Counting Of Time. Whenever days are to be counted under this Agreement, the first day will not be counted and the last day
will be counted.

 

10.7          
Notices. All notices, consents and other formal or legal communications hereunder to any Party will be deemed to be sufficient
if contained in a written instrument delivered in person, including delivery by recognized express courier, fees prepaid, or sent
by electronic mail with confirmed receipt (“email”) in each case addressed as set forth below such Party’s
signature below, or to such other address as may hereinafter be designated in writing by the recipient to the sender pursuant to
this Section 10.7. Notices hereunder may not be sent by facsimile or by mail. All such notices, consents and communications
will be deemed to have been received in the case of personal delivery, including delivery by express courier, on the date of such
delivery, or in the case of email transmission, upon confirmation of transmission.

 

10.8          
No Waiver. No failure to delay on the part of either Party in exercising any right or remedy hereunder will operate as a
waiver thereof, nor will any single or partial exercise of any such right or remedy preclude any other or further exercise thereof
or of any other right or remedy. No provision of this Agreement may be waived except in a writing signed by the Party granting
such waiver.

 

10.9          
Expenses. Each Party will, except as otherwise set forth specifically in this Agreement bear such Party’s own fees
and expenses incurred with respect to the negotiation and execution of this Agreement and with respect to the transactions contemplated
hereby.

 

10.10       
Severability. If any Section, or portion thereof, of this Agreement is held invalid by reason of any law, statute, or regulation
existing now or in the future in any jurisdiction by any court of competent authority or by a legally enforceable directive of
any governmental body, such section or portion thereof will be validly reformed so as to approximate the intent of the Parties
as nearly as possible and, if unreformable, will be deemed divisible and deleted with respect to such jurisdiction, but the Agreement
will not otherwise be affected.

 

10.11       
Further Actions and Documents. Each Party will execute, acknowledge and deliver all such further instruments, and to
do all such further acts, as may be reasonably necessary or appropriate to carry out the intent and purposes of this Agreement.

 

10.12       
Entire Agreement; Amendment. This Agreement, together with the CDA, constitutes and contains the entire understanding and
agreement of the Parties respecting the subject matter hereof and cancels and supersedes any and all prior and contemporaneous
negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such subject
matter. If the terms of this Agreement conflict with any order, the terms of this Agreement will control and prevail, and no terms,
provisions or conditions of any purchase order, invoice or other business form or written authorization used unilaterally (as opposed
to matters agreed to in writing by the Parties together as provided herein) by either Party as to the matters governed by this
Agreement will have any effect on the rights, duties or obligations hereunder or otherwise modify this Agreement. No agreement
or understanding varying or extending this Agreement will be binding upon either Party, and no amendment hereto, will be valid
unless set forth in a writing which specifically refers to the Agreement and the relevant matter, and that is signed by duly authorized
officers or representatives of the respective Parties, and the provisions of the Agreement not specifically amended thereby will
remain in full force and effect. Nothing in this Agreement removes or overrides any right of action by any Party in respect of
any fraudulent misrepresentation, fraudulent concealment or other fraudulent action by the other Party. This Agreement binds the
Parties’ successors and permitted assigns. In the event of a conflict between the terms of this Agreement and the Quality
Agreement, the terms of the Quality Agreement will govern with respect to quality and technical terms, and the terms of this Agreement
will govern all other matters.

 

    	 	10	 

    	BryoLogyx/Neurotrope—Bryostatin-1 Supply Agreement

    

 

10.13       
Construction; References. This Agreement has been negotiated by the Parties and their respective counsel. This Agreement
will be fairly interpreted in accordance with its terms and without any strict construction in favor of or against any Party, and
any ambiguity will not be interpreted against the drafting Party. References to “Sections” herein are to Sections hereof.

 

10.14       
Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but which together
will constitute one and the same instrument. Any signature page delivered by electronic image transmission, including without limitation
a PDF by email, will be binding to the same extent as an original signature page.

 

[Signature page follows]

 

    	 	11	 

    	BryoLogyx/Neurotrope—Bryostatin-1 Supply Agreement

    

  

IN WITNESS WHEREOF,
the Parties have caused their duly authorized representatives to execute this Agreement.

 

	Neurotrope bioscience, Inc. 	BRYOLOGYX INC.
	 	 
	By: /s/ Robert Weinstein	By:  /s/ Thomas M. Loarie
	Robert Weinstein	Thomas M. Loarie
	Chief Financial Officer	Chief Executive Officer
	Date signed:  June 9, 2020	Date signed:  June __, 2020

	Address:	Attention: CFO	Address: 	Attention:  CEO
	 	1185 Avenue of the Americas	 	2485 Holly Oak Drive
	 	New York, NY 10036	 	Danville, CA 94506-2043
	 	Email: rweinstein@neurotropebioscience.com	 	Email:  tloarie@bryologyx.com

 

 

 

 

    	 	12	 

    	BryoLogyx/Neurotrope—Bryostatin-1 Supply Agreement

    

 

EXHIBIT A

 

SPECIFICATIONS

 

[Note: These are initial specifications
as at the Effective Date, and are to be updated with completion of analytical method development to confirm final specifications
and provided that such updated specification will be set forth on this Exhibit A at such time, as an automatic amendment of this
Exhibit A.]

 

	Test	Description	Acceptance Criteria	 
	Physical description	Visual Assessment	White to off-white	 
	Identity	1H NMR	Conforms to structure	 
	HPLC	Sample retention time corresponds to  reference marker retention time (Ratio agreement 0.95 – 1.05)	 
	Chemical Purity (% area)	HPLC	NLT 96.0%	 
	Optical rotation	Polarimeter	Report results	 
	 
	Potency (%w/w)	Quantitative NMR	96-104%	 
	Individual and Total Related Substances (% area)	HPLC	Specified  and  Unspecified Impurities: report	 
	Total Impurities: NMT 4.0%	 
	
        Residual Solvents l
	GC	t-Butylmethylether: NMT 5000 ppm	 
	Dicholoromethane: NMT 600 ppm	 
	Ethylacetate : NMT 5000 ppm	 
	n-Heptane: NMT 5000 ppm	 
	Methanol: NMT 3000 ppm	 
	Tetrahydrofuran: NMT 720 ppm	 
	Toluene : NMT 890 ppm	 
	Melting Point (°C)	DSC	Report	 
	Water Content (%)	Karl Fisher	Report results (%)	 
	Microbial (cfu/g)	USP	
        Total Aerobic Microbial Count: NMT 103

        Total Yeast and Mold Count: NMT 102
	 

 

    	 	13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]